Azapine condensed ring compounds and their medical uses
By synthesizing azeotropic fused-ring compounds, the problem of the lack of RIP1 kinase inhibitors in the prior art has been solved, and effective inhibition of RIP1 kinase has been achieved for the treatment of related inflammatory and autoimmune diseases.
Patent Information
- Application Number
- CN202180012105.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2020-05-14
- Filing Date
- 2021-05-13
- Publication Date
- 2024-11-22
- Estimated Expiration
- 2041-05-13
AI Technical Summary
The lack of effective RIP1 kinase inhibitors in current technologies results in insufficient inhibition of RIP1 kinase activity, leading to poor treatment outcomes for related inflammatory and tissue damage diseases.
A series of azeotropic fused-ring compounds were designed and synthesized, exhibiting inhibitory activity against RIP1, for the development of drugs to prevent or treat diseases related to RIP1 activity.
A novel RIP1 inhibitor has been developed that can effectively inhibit RIP1 kinase activity, reduce inflammatory responses and tissue damage, and can be applied to the treatment of various inflammatory and autoimmune diseases.
Smart Images

Figure CN115038707B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to an azapine fused ring compound and its medical use. Specifically, the present invention relates to an azapine fused ring compound represented by general formula (I), a preparation method thereof, a pharmaceutical composition containing the same, and its use as a receptor interacting protein kinase 1 (RIP1) inhibitor for treating diseases related to RIP1 activity. Background Art
[0002] Apoptosis and necrosis are two ways of cell death. Passive cell death and cell necrosis caused by environmental factors play an important role in pathological and physiological processes such as inflammatory response. RIP1 is at the intersection of multiple inflammation and cell death-related signaling pathways, and participates in regulating multiple downstream signaling pathways such as TNF-activated NF-κB, apoptosis, and necrosis.
[0003] RIP1 can promote inflammatory responses by mediating the NF-κB pathway, but it is worth noting that the activation of the NF-κB pathway and TNF-induced apoptosis do not require the kinase activity of RIP1, and RIP1 kinase inhibition has no effect on TNF-induced NF-κB pathway activation. However, the kinase activity of RIP1 can also promote the occurrence and development of inflammation through multiple pathways such as cell necrosis, inflammasomes, and TNF production.
[0004] RIP1 kinase-mediated cell necrosis and inflammation: apoptotic cells can be quickly cleared by the body before the cell membrane ruptures, while necrotic cells are cleared more slowly. After the cell membrane ruptures, a large amount of dangerous contents in the cytoplasm are released and are regarded as pathogen-like substances by the body, activating many pattern recognition receptors and severely enhancing the inflammatory response. Cell necrosis is also considered to be an important factor in the rapid development and severe symptoms of related inflammatory diseases.
[0005] RIP1 kinase and inflammasomes: Like TNF-α, IL-1β is also a key pro-inflammatory factor. For example, in the development of RA, IL-1β aggravates the destruction of cartilage, bone tissue, and periarticular soft tissue by acting on synovial fibroblasts and chondrocytes. IL-1β secretion requires the assistance of two pathways: first, pathways such as TLR4 and TNF promote the expression of IL-1β / IL-18 precursors; then, the formed inflammasome platforms such as NLPR3 promote the maturation of IL-1β / IL-18 precursors. Inflammasomes are closely related to the development and progression of autoimmune diseases such as RA and psoriasis. The activation of inflammasomes depends on RIP1 and RIP3 and their kinase activity. RIP1 and RIP3 can amplify the expression of IL-1β, and this process is independent of cell necrosis.
[0006] RIP1 kinase-dependent mediation of IL-1α production: Protein tyrosine phosphatase SHP-1 plays an important role in immune signaling pathways. SHP-1 mutant mice produce a large number of inflammatory factors accompanied by inflammatory diseases such as arthritis, but the mechanism is unknown. Specific SHP-1 mutant mice can spontaneously develop severe inflammation, and the symptoms are similar to human neutrophilic dermatosis. In this model, RIP1 kinase is dependent on promoting IL-1α production, which can mediate and amplify inflammation and tissue damage, all of which are independent of inflammasomes, IL-1β and RIP3. RIP1 kinase inhibition can prevent the occurrence of related inflammation and damage, and NF-κB and ERK inhibition can alleviate RIP1-mediated inflammatory factor production. Therefore, inflammation and tissue damage in SHP-1 mutant mice depend on RIP1 kinase-mediated IL-1α production, and the mechanism is related to RIP1 kinase regulating NF-κB and ERK pathways.
[0007] RIP1 kinase-dependent mediation of TNFα production: cIAP can inhibit RIP1 activity through ubiquitination, and cIAP inhibitors such as Smac can induce TNFα production and cell death, but the mechanism is unknown. TNFα inhibition can prevent cell death induced by caspase inhibition, indicating that caspase e inhibition may induce TNFα production. RIP1 kinase inhibition can prevent cell death induced by caspase inhibition. Therefore, in the case of caspase inhibition, RIP1 may serve as an upstream mechanism for TNFα production. Recent studies have shown that RIP1 kinase can interact with EDD to induce JNK pathway activation and TNFα production. This pathway specifically corresponds to caspase inhibition, indicating that RIP1 kinase activity not only regulates cell necrosis downstream of TNFR1, but also plays an important role in mediating TNFα production.
[0008] In recent years, some genetic evidence (such as RIP1 kinase inactivation mutations) and related studies on RIP1 kinase inhibitor tool molecules (such as Nec-1) have further confirmed that RIP1 kinase plays an important role in the occurrence and development of some inflammatory and various tissue damage diseases. RIP1 kinase inactivation mutations can completely prevent multi-organ inflammatory phenotypes, especially skin inflammation; RIP1 kinase inhibition can prevent renal injury caused by ischemia-reperfusion in renal transplant animal models; RIP1 kinase inhibitor Nec-1 prevents myocardial infarction and cardiac hypoxia; RIP1 kinase inhibitor Nec-1 prevents cone cell death, dsRNA-induced retinal degeneration, and pigmentary retinitis.
[0009] Unlike RIP1 deficiency, which causes animal death, RIP1 kinase-inactivated mutant mice can survive normally and resist necrotic stimulation. Therefore, the death caused by RIP1 deficiency is not related to kinase activity. Ripk1D138N / D138N and RipkK45A / K45A kinase-inactivated mutant mice have no obvious phenotype changes, indicating that RIP1 kinase activity is a relatively safe target. In contrast, RIP3 kinase-inactivated mutant mice lose weight rapidly and die.
[0010] Given the important role that RIP1 kinase plays in the development of inflammation, RIP1 kinase inhibitors for the treatment of inflammatory diseases have received a certain amount of attention from leading global pharmaceutical companies. Among them, GSK's representative compound GSK2982772 has begun clinical phase II research; Roche also has molecules in the preclinical research stage. However, no RIP1 kinase inhibitors have been launched on the market so far, and researchers need to develop more RIP1 kinase inhibitor molecules in order to select better compounds for the treatment of related diseases and inflammation. Summary of the invention
[0011] After intensive research, the inventors have designed and synthesized a series of azapine fused ring compounds, which show inhibitory activity on receptor interacting protein kinase 1 (RIP1) and can be developed as drugs for preventing or treating diseases related to RIP1 activity.
[0012] Therefore, the object of the present invention is to provide a compound represented by general formula (I) or its mesomorph, racemate, enantiomer, diastereoisomer, or mixture thereof, or a pharmaceutically acceptable salt thereof.
[0013]
[0014] in,
[0015] X is selected from -O-, -S(O) m -、-NR a -,-CR'R"-;
[0016] Y 1 and Y 2 Each independently selected from O or S;
[0017] Z 1 and Z 2 are each independently selected from C or N atoms;
[0018] L is selected from a single bond, -O-, -S(O) m -、-NR a -、-(CR a R b ) n -、-(CR aR b ) n O-、-(CR a R b ) n S-and-(CR a R b ) n NR a -;
[0019] Ring A is selected from aryl, heteroaryl, cycloalkyl and heterocyclyl, wherein the aryl, heteroaryl, cycloalkyl and heterocyclyl are optionally further substituted by one or more R 9 replace;
[0020] Ring B is an aromatic ring or an aromatic heterocyclic ring, which is optionally further substituted with one or more R 8 replace;
[0021] Ring C is a nitrogen-containing heterocyclic ring, which is optionally further substituted with one or more R 7 replace;
[0022] R 1 and R 2 Together with the atoms they are attached to form C 6-10 aryl, 6- to 10-membered heteroaryl, 6- to 10-membered heterocyclic group or C 6-10 Cycloalkyl, or R 2 and R 3 Together with the atoms they are attached to form C 6-10 aryl, 6- to 10-membered heteroaryl, 6- to 10-membered heterocyclic group or C 6-10 Cycloalkyl, or R 3 and R 4 Together with the atoms they are attached to form C 6-10 aryl, 6- to 10-membered heteroaryl, 6- to 10-membered heterocyclic group or C 6-10 Cycloalkyl, wherein the C 6-10 aryl, 6- to 10-membered heteroaryl, 6- to 10-membered heterocyclic group or C 6-10 The cycloalkyl group is optionally further substituted with one or more R 6 Replace; where:
[0023] When R 1 and R 2 Together with the atoms they are attached to form C 6-10 aryl, 6- to 10-membered heteroaryl, 6- to 10-membered heterocyclic group or C 6-10 When cycloalkyl, R 3 and R 4 Each independently selected from R 6 ;or
[0024] When R 2 and R 3Together with the atoms they are attached to form C 6-10 aryl, 6- to 10-membered heteroaryl, 6- to 10-membered heterocyclic group or C 6-10 When cycloalkyl, R 1 and R 4 Each independently selected from R 6 ;or
[0025] When R 3 and R 4 Together with the atoms they are attached to form C 6-10 aryl, 6- to 10-membered heteroaryl, 6- to 10-membered heterocyclic group or C 6-10 When cycloalkyl, R 1 and R 2 Each independently selected from R 6 ;
[0026] R 5 is selected from the group consisting of hydrogen, alkyl, haloalkyl, cycloalkyl and halocycloalkyl;
[0027] Each R 6 are each independently selected from hydrogen, halogen, amino, nitro, cyano, hydroxyl, mercapto, oxo, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, -NR a R b 、-C(O)R a 、-O(O)CR a 、-C(O)OR a 、-C(O)NR a R b 、-NHC(O)R a 、-S(O) m R a 、-S(O) m UR a R b 、-NHS(O) m R a and -P(O)(R a )2, wherein the alkyl, alkoxy, cycloalkyl, heterocyclic, aryl, heteroaryl are optionally further substituted by one or more groups selected from deuterium atoms, halogen, amino, nitro, cyano, oxo, hydroxyl, thiol, carboxyl, ester, alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, heterocyclic, aryl, heteroaryl;
[0028] Each R 7 are each independently selected from hydrogen, halogen, amino, nitro, cyano, hydroxyl, mercapto, oxo, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, -NR a R b 、-C(O)R a 、-O(O)CRa 、-C(O)OR a 、-C(O)NR a R b 、-NHC(O)R a 、-S(O) m R a 、-S(O) m UR a R b , and -NHS(O) m R a ; wherein the alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl are optionally further substituted by one or more groups selected from halogen, amino, nitro, cyano, oxo, hydroxyl, thiol, carboxyl, ester, alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl;
[0029] Each R 8 are each independently selected from hydrogen, halogen, amino, nitro, cyano, hydroxyl, mercapto, oxo, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, -NR a R b 、-C(O)R a 、-O(O)CR a 、-C(O)OR a 、-C(O)NR a R b 、-NHC(O)R a 、-S(O) m R a 、-S(O) m NR a R b , and -NHS(O) m R a ; wherein the alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl are optionally further substituted by one or more groups selected from halogen, amino, nitro, cyano, oxo, hydroxyl, thiol, carboxyl, ester, alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl;
[0030] Each R 9 are each independently selected from hydrogen, halogen, amino, nitro, cyano, hydroxyl, mercapto, oxo, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, -NR a R b 、-C(O)R a 、-O(O)CR a 、-C(O)OR a 、-C(O)NR a R b 、-NHC(O)Ra 、-S(O) m R a 、-S(O) m NR a R b , and -NHS(O) m R a ; wherein the alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl are optionally further substituted by one or more groups selected from halogen, amino, nitro, cyano, oxo, hydroxyl, thiol, carboxyl, ester, alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl;
[0031] R' and R" are each independently selected from hydrogen, halogen, alkyl, haloalkyl;
[0032] R a and R b each independently selected from hydrogen, halogen, hydroxy, nitro, cyano, oxo, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are optionally further substituted with one or more groups selected from halogen, amino, nitro, cyano, hydroxy, thiol, carboxyl, ester, oxo, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl;
[0033] or R a and R b Together with the atoms to which they are attached, they form a cycloalkyl or heterocyclyl group, which is optionally further substituted with one or more groups selected from halogen, amino, nitro, cyano, oxo, hydroxyl, mercapto, carboxyl, ester, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl;
[0034] m is 0, 1 or 2;
[0035] n is an integer of 0-3.
[0036] In a preferred embodiment, the compound represented by general formula (I) according to the present invention or its mesoform, racemate, enantiomer, diastereomer, or mixture thereof, or pharmaceutically acceptable salt thereof, is a compound represented by general formula (II) or its mesoform, racemate, enantiomer, diastereomer, or mixture thereof, or pharmaceutically acceptable salt thereof,
[0037]
[0038] in,
[0039] Ring D is selected from C 6-10 aryl, 6- to 10-membered heteroaryl, 6- to 10-membered heterocyclic group or C 6-10Cycloalkyl, preferably phenyl, 6-8 membered heteroaryl, 6-8 membered heterocyclic group, C 6-8 Cycloalkyl, wherein the aryl, heteroaryl, heterocyclic and cycloalkyl are optionally further selected from halogen, nitro, cyano, hydroxyl, mercapto, oxo, alkyl, -NR a R b 、-C(O)R a 、-O(O)CR a 、-C(O)OR a 、-C(O)NR a R b 、-NHC(O)R a 、-S(O) m R a 、-S(O) m NR a R b 、-NHS(O) m R a and -P(O)(R a )2 is substituted with one or more groups;
[0040] R 1 and R 2 Each is independently selected from hydrogen, halogen, alkyl;
[0041] R a and R b each independently selected from hydrogen, halogen, hydroxyl, nitro, cyano, oxo, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are optionally further substituted with one or more groups selected from deuterium atoms, halogen, amino, nitro, cyano, hydroxyl, thiol, carboxyl, ester, oxo, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl;
[0042] or R a and R b Together with the atoms to which they are attached, they form a cycloalkyl or heterocyclyl group, which is optionally further substituted with one or more groups selected from halogen, amino, nitro, cyano, oxo, hydroxyl, mercapto, carboxyl, ester, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl;
[0043] m is 0, 1 or 2;
[0044] X, Y 1 , Y 2 , Z 1 , Z 2 , L, Ring A, Ring B, Ring C, R 5 As defined in general formula (I).
[0045] In another preferred embodiment, the compound of general formula (I) according to the present invention or its mesoform, racemate, enantiomer, diastereomer, or mixture thereof, or pharmaceutically acceptable salt thereof, is a compound of general formula (III) or its mesoform, racemate, enantiomer, diastereomer, or mixture thereof, or pharmaceutically acceptable salt thereof,
[0046]
[0047] in,
[0048] Ring E is selected from C 6-10 aryl, 6- to 10-membered heteroaryl, 6- to 10-membered heterocyclic group or C 6-10 Cycloalkyl, preferably phenyl, 6-8 membered heteroaryl, 6-8 membered heterocyclic group, C 6-8 Cycloalkyl, wherein the aryl, heteroaryl, heterocyclic and cycloalkyl are optionally further selected from halogen, nitro, cyano, hydroxyl, mercapto, oxo, alkyl, -NR a R b 、-C(O)R a 、-O(O)CR a 、-C(O)OR a 、-C(O)NR a R b 、-NHC(O)R a 、-S(O) m R a 、-S(O) m NR a R b 、-NHS(O) m R a and -P(O)(R a )2 is substituted with one or more groups;
[0049] R 1 and R 4 Each is independently selected from hydrogen, halogen, alkyl;
[0050] R a and R b each independently selected from hydrogen, halogen, hydroxy, nitro, cyano, oxo, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are optionally further substituted with one or more groups selected from halogen, amino, nitro, cyano, hydroxy, thiol, carboxyl, ester, oxo, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl;
[0051] or R a and R bTogether with the atoms to which they are attached, they form a cycloalkyl or heterocyclyl group, which is optionally further substituted with one or more groups selected from halogen, amino, nitro, cyano, oxo, hydroxyl, mercapto, carboxyl, ester, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl;
[0052] m is 0, 1 or 2;
[0053] X, Y 1 , Y 2 , Z 1 , Z 2 , L, Ring A, Ring B, Ring C, R 5 As defined in general formula (I).
[0054] In another preferred embodiment, the compound of general formula (I) according to the present invention, or its mesoform, racemate, enantiomer, diastereomer, or mixture thereof, or pharmaceutically acceptable salt thereof, is a compound of general formula (IV), or its mesoform, racemate, enantiomer, diastereomer, or mixture thereof, or pharmaceutically acceptable salt thereof,
[0055]
[0056] in:
[0057] Ring F is selected from C 6-10 aryl, 6- to 10-membered heteroaryl, 6- to 10-membered heterocyclic group or C 6-10 Cycloalkyl, preferably phenyl, 6-8 membered heteroaryl, 6-8 membered heterocyclic group, C 6-8 Cycloalkyl, wherein the aryl, heteroaryl, heterocyclic and cycloalkyl are optionally further selected from halogen, nitro, cyano, hydroxyl, mercapto, oxo, alkyl, -NR a R b 、-C(O)R a 、-O(O)CR a 、-C(O)OR a 、-C(O)NR a R b 、-NHC(O)R a 、-S(O) m R a 、-S(O) m NR a R b 、-NHS(O) m R a and -P(O)(R a )2 is substituted with one or more groups;
[0058] R 3 and R 4Each is independently selected from hydrogen, halogen, alkyl;
[0059] R a and R b each independently selected from hydrogen, halogen, hydroxy, nitro, cyano, oxo, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are optionally further substituted with one or more groups selected from halogen, amino, nitro, cyano, hydroxy, thiol, carboxyl, ester, oxo, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl;
[0060] or R a and R b Together with the atoms to which they are attached, they form a cycloalkyl or heterocyclyl group, which is optionally further substituted with one or more groups selected from halogen, amino, nitro, cyano, oxo, hydroxyl, mercapto, carboxyl, ester, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl;
[0061] m is 0, 1 or 2;
[0062] X, Y 1 , Y 2 , Z 1 , Z 2 , L, Ring A, Ring B, Ring C, R 5 As defined in general formula (I).
[0063] In a preferred embodiment, the compound represented by the general formula (II), (III) and (IV) or its meso form, racemate, enantiomer, diastereoisomer, or mixture thereof, or a pharmaceutically acceptable salt thereof,
[0064] in:
[0065] R a and R b Each is independently selected from hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl is optionally further substituted by one or more groups selected from halogen, amino, nitro, cyano, hydroxyl, thiol, carboxyl, ester, oxo, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl;
[0066] or R a and R b Together with the atoms to which they are attached, they form a 5-7 membered nitrogen-containing heterocyclic group, which is optionally further substituted by one or more groups selected from halogen, amino, nitro, cyano, oxo, hydroxyl, thiol, carboxyl, ester, alkyl, alkoxy, cycloalkyl, heterocyclic, aryl, and heteroaryl.
[0067] In another preferred embodiment, the compound represented by general formula (II) or its meso form, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt thereof,
[0068] Wherein, ring D is selected from C 6-8 Cycloalkyl or 6-8 membered heterocyclic group, preferably 6 membered heterocyclic group, more preferably piperidinyl, morpholinyl, dioxinyl; the heterocyclic group is optionally further selected from halogen, cyano, oxo, C 1-6 Alkyl, -C(O)R a 、-C(O)NR a R b 、-S(O) m R a and -S(O) m NR a R b One or more groups are substituted;
[0069] R a Selected from hydrogen, C 1-6 Alkyl, C 3-6 Cycloalkyl, 5-6 membered heterocyclic group, wherein the C 1-6 Alkyl, C 3-6 Cycloalkyl, 5-6 membered heterocyclic group may be further selected from deuterated, halogen, C 1-6 One or more groups of the alkyl group are substituted;
[0070] R b Selected from hydrogen or C 1-6 alkyl;
[0071] m is 1 or 2.
[0072] In another preferred embodiment, the compound represented by general formula (III) or its meso form, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt thereof,
[0073] in,
[0074] Ring E is selected from C 6-8 Cycloalkyl or 6-8 membered heterocyclic group, preferably 6 membered cycloalkyl or 6 membered heterocyclic group, more preferably cyclohexyl, piperidinyl, morpholinyl, dioxinyl; the cycloalkyl or heterocyclic group is optionally further selected from halogen, cyano, oxo, C 1-6 Alkyl, -C(O)R a 、-C(O)NR a R b 、-S(O) m R a and -S(O) m NR a Rb One or more groups are substituted;
[0075] R a Selected from hydrogen, C 1-6 Alkyl, C 3-6 Cycloalkyl, 5-6 membered heterocyclic group, wherein the C 1-6 Alkyl, C 3-6 Cycloalkyl, 5-6 membered heterocyclic group may be further selected from deuterated, halogen, C 1-6 One or more groups of the alkyl group are substituted;
[0076] R b Selected from hydrogen or C 1-6 alkyl;
[0077] m is 1 or 2.
[0078] In another preferred embodiment, the compound represented by general formula (IV) or its mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt thereof,
[0079] in,
[0080] Ring F is selected from C 6-8 Cycloalkyl or 6-8 membered heterocyclic group, preferably 6 membered cycloalkyl or 6 membered heterocyclic group, more preferably cyclohexyl, piperidinyl, morpholinyl, dioxinyl; the cycloalkyl or heterocyclic group is optionally further selected from halogen, cyano, oxo, C 1-6 Alkyl, -C(O)R a 、-C(O)NR a R b 、-S(O) m R a and -S(O) m NR a R b One or more groups are substituted;
[0081] R a Selected from hydrogen, C 1-6 Alkyl, C 3-6 Cycloalkyl, 5-6 membered heterocyclic group, wherein the C 1-6 Alkyl, C 3-6 Cycloalkyl, 5-6 membered heterocyclic group may be further selected from deuterated, halogen, C 1-6 One or more groups of the alkyl group are substituted;
[0082] R b Selected from hydrogen or C 1-6 alkyl;
[0083] m is 1 or 2.
[0084] In another preferred embodiment, according to the compound of general formula (I) of the present invention or its racemate, racemate, enantiomer, diastereomer, or mixture thereof, or pharmaceutically acceptable salt thereof, X is -O-.
[0085] In another preferred embodiment, the compound represented by the general formula (I) according to the present invention or its mesomorph, racemate, enantiomer, diastereoisomer, or mixture thereof, or pharmaceutically acceptable salt thereof, wherein ring C is a 5- to 8-membered nitrogen-containing heterocyclic ring, preferably a piperidine ring, a tetrahydropyrrole ring, a piperazine ring, a dihydropyrrole ring, a tetrahydropyridine ring or a homopiperazine ring, more preferably a piperidine ring, which is optionally further substituted with one or more R 7 replace;
[0086] Each R 7 are each independently selected from hydrogen, halogen, amino, nitro, cyano, hydroxyl, mercapto, oxo, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, -NR a R b 、-C(O)R a 、-O(O)CR a 、-C(O)OR a 、-C(O)NR a R b 、-NHC(O)R a 、-S(O) m R a 、-S(O) m NR a R b , and -NHS(O) m R a ; wherein the alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl are optionally further substituted by one or more groups selected from halogen, amino, nitro, cyano, oxo, hydroxyl, thiol, carboxyl, ester, alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl;
[0087] in:
[0088] R a and R b each independently selected from hydrogen, halogen, hydroxy, nitro, cyano, oxo, alkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl, wherein the alkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are optionally further substituted with one or more groups selected from halogen, amino, nitro, cyano, hydroxy, thiol, carboxyl, ester, oxo, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl;
[0089] or R a and R bTogether with the atoms to which they are attached, they form a cycloalkyl or heterocyclyl group, which is optionally further substituted with one or more groups selected from halogen, amino, nitro, cyano, oxo, hydroxyl, mercapto, carboxyl, ester, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl;
[0090] m is 0, 1 or 2.
[0091] In another preferred embodiment, according to the compound represented by the general formula (I) of the present invention or its mesomorph, racemate, enantiomer, diastereoisomer, or mixture thereof, or pharmaceutically acceptable salt thereof, wherein ring B is a 6- to 10-membered aromatic ring or a 5- to 6-membered aromatic heterocyclic ring, preferably a benzene ring, a pyridine ring, a pyrimidine ring, a pyrazine ring, a pyridazine ring, a pyrrole ring, a pyrazole ring, an imidazole ring, an oxazole ring, a thiazole ring, an isoxazole ring, an isothiazole ring, an oxadiazole ring, a thiadiazole ring, or a triazole ring, more preferably a pyrazole ring, an imidazole ring, or a triazole ring, which is optionally further replaced by one or more R 8 replace;
[0092] Each R 8 are each independently selected from hydrogen, halogen, amino, nitro, cyano, hydroxyl, mercapto, oxo, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, -NR a R b 、-C(O)R a 、-O(O)CR a 、-C(O)OR a 、-C(O)NR a R b 、-NHC(O)R a 、-S(O) m R a 、-S(O) m NR a R b , and -NHS(O) m R a ; wherein the alkyl, alkoxy, cycloalkyl, heterocyclic, aryl, heteroaryl are optionally further substituted by one or more groups selected from halogen, amino, nitro, cyano, oxo, hydroxyl, sulfhydryl, carboxyl, ester, alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, heterocyclic, aryl, heteroaryl; preferably R 8 is a halogen;
[0093] in:
[0094] R a and R beach independently selected from hydrogen, halogen, hydroxy, nitro, cyano, oxo, alkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl, wherein the alkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are optionally further substituted with one or more groups selected from halogen, amino, nitro, cyano, hydroxy, thiol, carboxyl, ester, oxo, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl;
[0095] or R a and R b Together with the atoms to which they are attached, they form a cycloalkyl or heterocyclyl group, which is optionally further substituted with one or more groups selected from halogen, amino, nitro, cyano, oxo, hydroxyl, mercapto, carboxyl, ester, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl;
[0096] m is 0, 1 or 2.
[0097] In another preferred embodiment, the compound represented by the general formula (I) according to the present invention or its mesomorph, racemate, enantiomer, diastereomer, or mixture thereof, or pharmaceutically acceptable salt thereof, wherein:
[0098] Selected from:
[0099]
[0100] in,
[0101] Y 2 Selected from O or S;
[0102] Z 1 and Z 2 are each independently selected from C or N atoms;
[0103] Ring B is a 6- to 10-membered aromatic ring or a 5- to 6-membered aromatic heterocyclic ring, preferably a benzene ring, a pyridine ring, a pyrimidine ring, a pyrazine ring, a pyridazine ring, a pyrrole ring, a pyrazole ring, an imidazole ring, an oxazole ring, a thiazole ring, an isoxazole ring, an isothiazole ring, an oxadiazole ring, a thiadiazole ring, or a triazole ring, more preferably a pyrazole ring, an imidazole ring, or a triazole ring, which is optionally further substituted with one or more R 8 replace;
[0104] Each R 7 Each is independently selected from hydrogen, halogen, amino, nitro, cyano, hydroxyl, mercapto, oxo, alkyl, alkoxy; or two adjacent R 7Together with the atoms to which they are attached, they form a heterocyclic group or a cycloalkyl group, wherein the alkyl, alkoxy, cycloalkyl, heterocyclic group is optionally further substituted with one or more groups selected from halogen, amino, nitro, cyano, oxo, hydroxyl, thiol, carboxyl, ester, alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, heterocyclic group, aryl, heteroaryl; preferably R 7 is hydrogen;
[0105] Each R 8 Each is independently selected from hydrogen, halogen, amino, nitro, cyano, hydroxyl, thiol, oxo, alkyl, alkoxy, cycloalkyl, heterocyclic, aryl, heteroaryl; wherein the alkyl, alkoxy, cycloalkyl, heterocyclic, aryl, heteroaryl is optionally further substituted by one or more groups selected from halogen, amino, nitro, cyano, oxo, hydroxyl, thiol, carboxyl, ester, alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, heterocyclic, aryl, heteroaryl; preferably R 8 is a halogen;
[0106] p is 0, 1, 2, 3 or 4, preferably 0.
[0107] In another preferred embodiment, the compound represented by the general formula (I) according to the present invention or its mesomorph, racemate, enantiomer, diastereomer, or mixture thereof, or pharmaceutically acceptable salt thereof, wherein:
[0108] Selected from:
[0109] Best
[0110] in,
[0111] Y 2 Selected from O or S;
[0112] Each R 8 Each is independently selected from hydrogen, halogen, amino, nitro, cyano, hydroxyl, thiol, oxo, alkyl, alkoxy, cycloalkyl, heterocyclic, aryl, heteroaryl; wherein the alkyl, alkoxy, cycloalkyl, heterocyclic, aryl, heteroaryl is optionally further substituted by one or more groups selected from halogen, amino, nitro, cyano, oxo, hydroxyl, thiol, carboxyl, ester, alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, heterocyclic, aryl, heteroaryl; preferably R 8 is a halogen;
[0113] q is 0, 1, or 2.
[0114] In another preferred embodiment, the compound represented by the general formula (I) according to the present invention or its mesomorph, racemate, enantiomer, diastereomer, or mixture thereof, or pharmaceutically acceptable salt thereof, wherein Y 2 is O.
[0115] In another preferred embodiment, the compound represented by the general formula (I) according to the present invention or its mesomorph, racemate, enantiomer, diastereomer, or mixture thereof, or pharmaceutically acceptable salt thereof, wherein Y 1 is O.
[0116] In another preferred embodiment, the compound represented by the general formula (I) according to the present invention or its mesomorph, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt thereof,
[0117] in,
[0118] Ring A is selected from aryl and heteroaryl, preferably phenyl, wherein the aryl or heteroaryl is optionally further substituted by one or more R 9 replace,
[0119] Each R 9 Each is independently selected from hydrogen, halogen, cyano, hydroxyl, oxo, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl and heteroaryl, preferably hydrogen, halogen, alkyl and alkoxy; wherein the alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl is optionally further substituted by one or more groups selected from halogen, amino, nitro, cyano, oxo, hydroxyl, thiol, carboxyl, ester, alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl.
[0120] In another preferred embodiment, the compound represented by the general formula (I) according to the present invention or its mesomorph, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt thereof,
[0121] Wherein, L is selected from -NR a -and-(CR a R b ) n -, preferably -(CR a R b ) n -;
[0122] R a and R b are each independently selected from hydrogen and C 1-6 alkyl;
[0123] n is an integer from 0 to 3, preferably 1;
[0124] L is more preferably -CH2-;
[0125] In another preferred embodiment, the compound represented by the general formula (I) according to the present invention or its mesomorph, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt thereof,
[0126] Among them, R 5 Selected from hydrogen, C 1-6 Alkyl and halogenated C 1-6 Alkyl, preferably hydrogen and C 1-6 alkyl.
[0127] Typical compounds of the present invention include, but are not limited to:
[0128]
[0129]
[0130]
[0131]
[0132]
[0133] Its meso form, racemate, enantiomer, diastereomer, or mixture form, or its pharmaceutically acceptable salt.
[0134] The present invention further provides a method for preparing the compound represented by general formula (I) according to the present invention or its mesomorph, racemate, enantiomer, diastereoisomer, or mixture thereof, or pharmaceutically acceptable salt thereof, which comprises the following steps:
[0135]
[0136] In the presence of a catalyst, compound I1 undergoes an intramolecular ring-closing reaction to obtain a compound of formula (I), wherein the catalyst is preferably trimethylaluminum;
[0137] Among them, X, Y 1 , Y 2 , Z 1 , Z 2 , L, Ring A, Ring B, Ring C, R 1 , R 2 , R 3 , R 4 , R 5 As defined in general formula (I).
[0138] The present invention further provides a pharmaceutical composition, which comprises a compound represented by the general formula (I) according to the present invention or its racemate, racemate, enantiomer, diastereomer, or a mixture thereof, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.
[0139] The present invention further relates to the use of the compound represented by the general formula (I) according to the present invention or its racemate, racemate, enantiomer, diastereomer, or mixture thereof, or its pharmaceutically acceptable salt or a pharmaceutical composition containing the same in the preparation of receptor interacting protein kinase 1 (RIP1) inhibitors.
[0140] The present invention further relates to the use of the compound represented by the general formula (I) according to the present invention or its mesomorph, racemate, enantiomer, diastereoisomer, or mixture thereof, or its pharmaceutically acceptable salt or pharmaceutical composition containing the same in the preparation of a drug for preventing or treating a disease associated with the activity of receptor interacting protein kinase 1, wherein the disease is preferably an inflammatory disease, an autoimmune disease or a nervous system disease, wherein the inflammatory disease and the autoimmune disease are, for example, rheumatoid arthritis, ulcerative colitis, Crohn's disease, psoriasis, retinal detachment, pigmentary retinitis, macular degeneration, pancreatitis, atopic dermatitis, spondyloarthritis, gout, juvenile idiopathic arthritis, systemic lupus erythematosus, Sjögren's syndrome, system scleroderma, antiphospholipid syndrome, vasculitis, osteoarthritis, nonalcoholic steatohepatitis, autoimmune hepatitis, autoimmune hepatobiliary disease, primary sclerosing cholangitis, nephritis, celiac disease, autoimmune thrombocytopenic purpura, transplant rejection, solid organ ischemia-reperfusion injury, sepsis, systemic inflammatory response syndrome, allergic diseases, asthma, atopic skin diseases, multiple sclerosis, type I diabetes, orbital necrotizing granulomatosis, pulmonary sarcoidosis, Behcet's disease, interleukin-1 converting enzyme-associated febrile syndrome, chronic obstructive pulmonary disease, tumor necrosis factor receptor-associated syndrome or periodontitis; the nervous system disease is such as Huntington's disease, Alzheimer's disease, Parkinson's disease or amyotrophic lateral sclerosis.
[0141] The present invention further relates to a compound represented by the general formula (I) according to the present invention or its racemate, racemate, enantiomer, diastereomer, or mixture thereof, or its pharmaceutically acceptable salt or a pharmaceutical composition containing the same, which is used as a receptor interacting protein kinase 1 (RIP1) inhibitor.
[0142] The present invention further relates to a compound represented by the general formula (I) according to the present invention or its mesomorph, racemate, enantiomer, diastereoisomer, or mixture thereof, or its pharmaceutically acceptable salt or a pharmaceutical composition comprising the same, which is used for preventing or treating a disease associated with the activity of receptor interacting protein kinase 1, wherein the disease is preferably an inflammatory disease, an autoimmune disease or a nervous system disease, wherein the inflammatory disease and the autoimmune disease are, for example, rheumatoid arthritis, ulcerative colitis, Crohn's disease, psoriasis, retinal detachment, pigmentary retinitis, macular degeneration, pancreatitis, atopic dermatitis, spondyloarthritis, gout, juvenile idiopathic arthritis, systemic lupus erythematosus, Sjögren's syndrome, systemic sclerosis Skin diseases, antiphospholipid syndrome, vasculitis, osteoarthritis, nonalcoholic steatohepatitis, autoimmune hepatitis, autoimmune hepatobiliary diseases, primary sclerosing cholangitis, nephritis, celiac disease, autoimmune thrombocytopenic purpura, transplant rejection, solid organ ischemia-reperfusion injury, sepsis, systemic inflammatory response syndrome, allergic diseases, asthma, atopic skin diseases, multiple sclerosis, type I diabetes, orbital necrotizing granulomatosis, pulmonary sarcoidosis, Behcet's disease, interleukin-1 converting enzyme-associated febrile syndrome, chronic obstructive pulmonary disease, tumor necrosis factor receptor-associated syndrome or periodontitis; the nervous system diseases are such as Huntington's disease, Alzheimer's disease, Parkinson's disease or amyotrophic lateral sclerosis.
[0143] The present invention further relates to a method for inhibiting receptor interacting protein kinase 1 (RIP1), which comprises administering to a patient in need thereof an effective amount of a compound represented by the general formula (I) according to the present invention or its racemate, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the same.
[0144] The present invention further relates to a method for preventing or treating a disease associated with the activity of receptor interacting protein kinase 1, comprising administering to a patient in need thereof an effective amount of a compound of general formula (I) according to the present invention or its mesomorph, racemate, enantiomer, diastereoisomer, or mixture thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the same; wherein the disease is preferably an inflammatory disease, an autoimmune disease or a nervous system disease, and the inflammatory disease and autoimmune disease are, for example, rheumatoid arthritis, ulcerative colitis, Crohn's disease, psoriasis, retinal detachment, pigmentary retinitis, macular degeneration, pancreatitis, atopic dermatitis, spondyloarthritis, gout, juvenile idiopathic arthritis, systemic lupus erythematosus The invention relates to an autoimmune disease, such as leukemia, leukoderma, sjögren's syndrome, systemic sclerosis, antiphospholipid syndrome, vasculitis, osteoarthritis, nonalcoholic steatohepatitis, autoimmune hepatitis, autoimmune hepatobiliary disease, primary sclerosing cholangitis, nephritis, celiac disease, autoimmune thrombocytopenic purpura, transplant rejection, solid organ ischemia-reperfusion injury, sepsis, systemic inflammatory response syndrome, allergic diseases, asthma, atopic skin diseases, multiple sclerosis, type I diabetes, orbital necrotizing granulomatosis, pulmonary sarcoidosis, Behcet's disease, interleukin-1 converting enzyme-associated febrile syndrome, chronic obstructive pulmonary disease, tumor necrosis factor receptor-associated syndrome or periodontitis; the neurological disease is such as Huntington's disease, Alzheimer's disease, Parkinson's disease or amyotrophic lateral sclerosis.
[0145] According to the conventional method in the field to which the present invention belongs, the compound represented by the general formula (I) of the present invention can form a pharmaceutically acceptable basic addition salt with a base. The base includes an inorganic base and an organic base, and the acceptable organic base includes diethanolamine, ethanolamine, N-methylglucamine, triethanolamine, tromethamine, etc., and the acceptable inorganic base includes aluminum hydroxide, calcium hydroxide, potassium hydroxide, sodium carbonate and sodium hydroxide, etc.
[0146] The pharmaceutical composition containing the active ingredient may be in a form suitable for oral administration, such as tablets, troches, lozenges, aqueous or oil suspensions, dispersible powders or granules, emulsions, hard or soft capsules, or syrups or elixirs. Oral compositions may be prepared according to any method known in the art for preparing pharmaceutical compositions, and such compositions may contain one or more ingredients selected from the following: sweeteners, flavoring agents, colorants and preservatives to provide pleasing and palatable pharmaceutical preparations. Tablets contain the active ingredient and non-toxic pharmaceutically acceptable excipients suitable for preparing tablets for mixing. These excipients may be inert excipients such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating agents and disintegrants such as microcrystalline cellulose, crosslinked sodium carboxymethyl cellulose, corn starch or alginic acid; binders such as starch, gelatin, polyvinyl pyrrolidone or gum arabic; and lubricants such as magnesium stearate, stearic acid or talc. These tablets may be uncoated or may be coated by known techniques which mask the taste of the drug or delay disintegration and absorption in the gastrointestinal tract, thereby providing a sustained release action over a longer period of time. For example, water soluble taste masking materials such as hydroxypropylmethylcellulose or hydroxypropylcellulose, or time extending materials such as ethylcellulose, cellulose acetate butyrate may be used.
[0147] Oral preparations may also be provided in hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent such as calcium carbonate, calcium phosphate or kaolin, or in soft gelatin capsules wherein the active ingredient is mixed with a water-soluble carrier such as polyethylene glycol or an oily vehicle such as peanut oil, liquid paraffin or olive oil.
[0148] Aqueous suspensions contain the active substance and excipients suitable for preparing aqueous suspensions for mixing. Such excipients are suspending agents, for example, sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethylcellulose, sodium alginate, polyvinylpyrrolidone and gum arabic; dispersants or wetting agents, which may be naturally occurring phosphatides such as lecithin, or condensation products of alkylene oxides with fatty acids, for example, polyoxyethylene stearate, or condensation products of ethylene oxide with long chain fatty alcohols, for example, heptadecaethyleneoxy cetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol, for example, polyethylene oxide sorbitan monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example, polyethylene oxide dehydrated sorbitan monooleate. The aqueous suspension may also contain one or more preservatives, for example ethylparaben or n-propylparaben, one or more coloring agents, one or more flavoring agents and one or more sweetening agents, for example sucrose, saccharin or aspartame.
[0149] Oil suspensions can be prepared by suspending the active ingredient in a vegetable oil such as peanut oil, olive oil, sesame oil or coconut oil, or a mineral oil such as liquid paraffin. The oil suspension may contain a thickener such as beeswax, hard paraffin or cetyl alcohol. The above-mentioned sweeteners and flavoring agents may be added to provide a palatable preparation. These compositions may be preserved by adding an antioxidant such as butylated hydroxyanisole or alpha-tocopherol.
[0150] Dispersible powders and granules suitable for preparing aqueous suspensions can provide the active ingredient and a dispersant or wetting agent, a suspending agent or one or more preservatives for mixing by adding water. Suitable dispersants or wetting agents and suspending agents are as described above. Other excipients such as sweeteners, flavoring agents and coloring agents can also be added. These compositions can be preserved by adding antioxidants such as ascorbic acid.
[0151] The pharmaceutical composition of the present invention can also be in the form of an oil-in-water emulsion. The oil phase can be a vegetable oil such as olive oil or peanut oil, or a mineral oil such as liquid paraffin or a mixture thereof. Suitable emulsifiers can be naturally occurring phospholipids, such as soybean lecithin, and esters or partial esters derived from fatty acids and hexitol anhydrides, such as sorbitan monooleate, and condensation products of the partial esters and ethylene oxide, such as polyethylene oxide sorbitol monooleate. Emulsions can also contain sweeteners, flavoring agents, preservatives, and antioxidants. Syrups and elixirs prepared with sweeteners such as glycerol, propylene glycol, sorbitol, or sucrose can be used. Such preparations can also contain a demulcent, a preservative, a coloring agent, and an antioxidant.
[0152] The pharmaceutical composition of the present invention may be in the form of a sterile injectable aqueous solution. Acceptable vehicles and solvents that may be used are water, Ringer's solution and isotonic sodium chloride solution. The sterile injectable preparation may be a sterile injectable oil-in-water microemulsion in which the active ingredient is dissolved in an oil phase. For example, the active ingredient is dissolved in a mixture of soybean oil and lecithin. The oil solution is then added to a mixture of water and glycerol and processed to form a microemulsion. The injection or microemulsion may be injected into the patient's bloodstream by local mass injection. Alternatively, the solution and microemulsion may be preferably administered in a manner that maintains a constant circulating concentration of the compound of the present invention. To maintain this constant concentration, a continuous intravenous drug delivery device may be used.
[0153] The pharmaceutical composition of the present invention can be in the form of a sterile injection water or oil suspension for intramuscular and subcutaneous administration. The suspension can be prepared by known techniques with the above-mentioned suitable dispersants or wetting agents and suspending agents. The sterile injection preparation can also be a sterile injection solution or suspension prepared in a non-toxic parenteral acceptable diluent or solvent, such as a solution prepared in 1,3-butanediol. In addition, sterile fixed oil can be conveniently used as a solvent or suspension medium. For this purpose, any blended fixed oil including synthetic glycerol mono- or di-esters can be used. In addition, fatty acids such as oleic acid can also be used to prepare injections.
[0154] The compounds of the invention may be administered in the form of suppositories for rectal administration. These pharmaceutical compositions may be prepared by mixing the drug with a suitable non-irritating excipient which is solid at ordinary temperatures but liquid in the rectum and which will dissolve in the rectum to release the drug. Such materials include cocoa butter, glycerinated gelatin, hydrogenated vegetable oils, polyethylene glycols of various molecular weights and mixtures of fatty acid esters of polyethylene glycol.
[0155] It is well known to those skilled in the art that the dosage of a drug depends on a variety of factors, including but not limited to the following factors: the activity of the specific compound used, the patient's age, the patient's weight, the patient's health condition, the patient's behavior, the patient's diet, the administration time, the administration method, the excretion rate, the combination of drugs, etc. In addition, the best treatment method, such as the mode of treatment, the daily dosage of the general compound or the type of pharmaceutically acceptable salt can be verified according to traditional treatment plans.
[0156] The present invention may contain the compound represented by the general formula (I), and a pharmaceutically acceptable salt, hydrate or solvate thereof as an active ingredient, mixed with a pharmaceutically acceptable carrier or excipient to prepare a composition, and prepared into a clinically acceptable dosage form. The derivatives of the present invention may be used in combination with other active ingredients, as long as they do not produce other adverse effects, such as allergic reactions, etc. The compounds of the present invention may be used as the sole active ingredient, or in combination with other drugs for treating diseases related to tyrosine kinase activity. Combination therapy is achieved by administering the individual therapeutic components simultaneously, separately or sequentially.
[0157] Detailed description of the invention
[0158] Unless stated otherwise, the terms used in the specification and claims have the following meanings.
[0159] The term "alkyl" refers to a saturated aliphatic hydrocarbon group, which is a straight or branched chain group containing 1 to 20 carbon atoms, preferably an alkyl group containing 1 to 12 carbon atoms, and more preferably an alkyl group containing 1 to 6 carbon atoms. Non-limiting examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2-methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1,3-dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2,3-dimethylbutyl, n-heptyl, 2-methylhexyl, 3-methylhexyl, 4-methylhexyl, 5-methylhexyl, 2, 3-Dimethylpentyl, 2,4-dimethylpentyl, 2,2-dimethylpentyl, 3,3-dimethylpentyl, 2-ethylpentyl, 3-ethylpentyl, n-octyl, 2,3-dimethylhexyl, 2,4-dimethylhexyl, 2,5-dimethylhexyl, 2,2-dimethylhexyl, 3,3-dimethylhexyl, 4,4-dimethylhexyl, 2-ethylhexyl, 3-ethylhexyl, 4-ethylhexyl, 2-methyl-2-ethylpentyl, 2-methyl-3-ethylpentyl, n-nonyl, 2-methyl-2-ethylhexyl, 2-methyl-3-ethylhexyl, 2,2-diethylpentyl, n-decyl, 3,3-diethylhexyl, 2,2-diethylhexyl, and various branched chain isomers thereof. More preferred are lower alkyl groups containing 1 to 6 carbon atoms, non-limiting examples of which include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2-methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1,3-dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2,3-dimethylbutyl, and the like. The alkyl group may be substituted or unsubstituted. When substituted, the substituent may be substituted at any available point of attachment. The substituent is preferably one or more of the following groups independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxy, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkyloxy, heterocycloalkyloxy, cycloalkylthio, heterocycloalkylthio, oxo, carboxyl or carboxylate.
[0160] The term "alkenyl" refers to an alkyl group as defined above consisting of at least two carbon atoms and at least one carbon-carbon double bond, such as vinyl, 1-propenyl, 2-propenyl, 1-, 2- or 3-butenyl, etc. The alkenyl group may be substituted or unsubstituted, and when substituted, the substituent is preferably one or more of the following groups independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxy, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkyloxy, heterocycloalkyloxy, cycloalkylthio, heterocycloalkylthio.
[0161] The term "alkynyl" refers to an alkyl group as defined above consisting of at least two carbon atoms and at least one carbon-carbon triple bond, such as ethynyl, propynyl, butynyl, etc. Alkynyl may be substituted or unsubstituted, and when substituted, the substituent is preferably one or more of the following groups independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxy, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkyloxy, heterocycloalkyloxy, cycloalkylthio, heterocycloalkylthio.
[0162] The term "cycloalkyl" refers to a saturated or partially unsaturated monocyclic or polycyclic cyclic hydrocarbon substituent, the cycloalkyl ring containing 3 to 20 carbon atoms, preferably 3 to 12 carbon atoms, more preferably 3 to 6 carbon atoms. Non-limiting examples of monocyclic cycloalkyls include cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cyclohexadienyl, cycloheptyl, cycloheptatrienyl, cyclooctyl, etc.; polycyclic cycloalkyls include spirocyclic, fused and bridged cycloalkyls.
[0163] The term "spirocycloalkyl" refers to a polycyclic group that shares a carbon atom (called a spiral atom) between 5 to 20 monocyclic rings, which may contain one or more double bonds, but no ring has a completely conjugated π electron system. Preferably, it is 6 to 14 yuan, more preferably 7 to 10 yuan. According to the number of spiral atoms shared between the rings, the spirocycloalkyl is divided into a single spiral cycloalkyl, a double spiral cycloalkyl or a multi-spirocycloalkyl, preferably a single spiral cycloalkyl and a double spiral cycloalkyl. More preferably, it is a 4 yuan / 4 yuan, 4 yuan / 5 yuan, 4 yuan / 6 yuan, 5 yuan / 5 yuan or 5 yuan / 6 yuan single spiral cycloalkyl. Non-limiting examples of spirocycloalkyl include:
[0164]
[0165] The term "condensed cycloalkyl" refers to a 5 to 20-membered, all-carbon polycyclic group in which each ring in the system shares a pair of adjacent carbon atoms with other rings in the system, wherein one or more rings may contain one or more double bonds, but no ring has a completely conjugated π electron system. Preferably, it is 6 to 14 members, more preferably 7 to 10 members. According to the number of constituent rings, it can be divided into a bicyclic, tricyclic, tetracyclic or polycyclic condensed cycloalkyl, preferably a bicyclic or tricyclic, more preferably a 5-membered / 5-membered or 5-membered / 6-membered bicyclic alkyl. Non-limiting examples of condensed cycloalkyls include:
[0166]
[0167] The term "bridged cycloalkyl" refers to a 5 to 20-membered, all-carbon polycyclic group in which any two rings share two carbon atoms that are not directly connected, which may contain one or more double bonds, but no ring has a completely conjugated π electron system. Preferably, it is 6 to 14 members, and more preferably 7 to 10 members. According to the number of constituent rings, it can be divided into a bicyclic, tricyclic, tetracyclic or polycyclic bridged cycloalkyl, preferably a bicyclic, tricyclic or tetracyclic, and more preferably a bicyclic or tricyclic. Non-limiting examples of bridged cycloalkyl include:
[0168]
[0169] The cycloalkyl ring may be fused to an aryl, heteroaryl or heterocycloalkyl ring, wherein the ring attached to the parent structure is a cycloalkyl, non-limiting examples of which include indanyl, tetrahydronaphthyl, benzocycloheptanyl, etc. The cycloalkyl may be optionally substituted or unsubstituted, and when substituted, the substituents are preferably one or more of the following groups independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxy, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkyloxy, heterocycloalkyloxy, cycloalkylthio, heterocycloalkylthio, oxo, carboxyl or carboxylate.
[0170] The term "heterocyclyl" refers to a saturated or partially unsaturated monocyclic or polycyclic hydrocarbon substituent containing 3 to 20 ring atoms, one or more of which is selected from nitrogen, oxygen or S(O). m(wherein m is an integer from 0 to 2) heteroatoms, but does not include -OO-, -OS- or -SS- ring parts, and the remaining ring atoms are carbon. Preferably, it contains 3 to 12 ring atoms, of which 1 to 4 are heteroatoms; most preferably, it contains 3 to 8 ring atoms, of which 1 to 3 are heteroatoms; most preferably, it contains 5 to 7 ring atoms, of which 1 to 2 or 1 to 3 are heteroatoms. Non-limiting examples of monocyclic heterocyclic groups include pyrrolidinyl, imidazolidinyl, tetrahydrofuranyl, tetrahydrothienyl, dihydroimidazolyl, dihydrofuranyl, dihydropyrazolyl, dihydropyrrolyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, homopiperazinyl, pyranyl, etc., preferably 1, 2, 5-oxadiazolyl, pyranyl or morpholinyl. Polycyclic heterocyclic groups include spirocyclic, fused ring and bridged heterocyclic groups.
[0171] The term "spiro heterocyclic group" refers to a polycyclic heterocyclic group in which the monocyclic rings of 5 to 20 members share one atom (called a spiro atom), wherein one or more of the ring atoms is selected from nitrogen, oxygen or S(O) m (wherein m is an integer 0 to 2) heteroatom, and the remaining ring atoms are carbon. It may contain one or more double bonds, but no ring has a completely conjugated π electron system. Preferably, it is 6 to 14 yuan, more preferably 7 to 10 yuan. According to the number of shared spiral atoms between rings, the spiral heterocyclic group is divided into a single spiral heterocyclic group, a double spiral heterocyclic group or a multi-spiro heterocyclic group, preferably a single spiral heterocyclic group and a double spiral heterocyclic group. More preferably, it is a 4 yuan / 4 yuan, 4 yuan / 5 yuan, 4 yuan / 6 yuan, 5 yuan / 5 yuan or 5 yuan / 6 yuan single spiral heterocyclic group. Non-limiting examples of spiral heterocyclic groups include:
[0172]
[0173] The term "fused heterocyclyl" refers to a polycyclic heterocyclic group of 5 to 20 members, each ring in the system shares a pair of adjacent atoms with other rings in the system, one or more rings may contain one or more double bonds, but no ring has a completely conjugated π electron system, wherein one or more ring atoms are selected from nitrogen, oxygen or S(O) m (wherein m is an integer from 0 to 2) heteroatoms, and the remaining ring atoms are carbon. Preferably 6 to 14 members, more preferably 7 to 10 members. According to the number of constituent rings, it can be divided into a bicyclic, tricyclic, tetracyclic or polycyclic fused heterocyclic group, preferably a bicyclic or tricyclic, more preferably a 5-membered / 5-membered or 5-membered / 6-membered bicyclic fused heterocyclic group. Non-limiting examples of fused heterocyclic groups include:
[0174]
[0175] The term "bridged heterocyclyl" refers to a 5- to 14-membered polycyclic heterocyclic group in which any two rings share two atoms that are not directly connected, which may contain one or more double bonds, but none of the rings has a completely conjugated π-electron system, and one or more of the ring atoms is selected from nitrogen, oxygen or S(O)m (wherein m is an integer from 0 to 2) heteroatoms, and the remaining ring atoms are carbon. Preferably, it is 6 to 14 members, and more preferably 7 to 10 members. According to the number of constituent rings, it can be divided into bicyclic, tricyclic, tetracyclic or polycyclic bridged heterocyclic groups, preferably bicyclic, tricyclic or tetracyclic, and more preferably bicyclic or tricyclic. Non-limiting examples of bridged heterocyclic groups include:
[0176]
[0177] The heterocyclyl ring may be fused to an aryl, heteroaryl or cycloalkyl ring, wherein the ring attached to the parent structure is a heterocyclyl, non-limiting examples of which include:
[0178] wait.
[0179] The heterocyclyl group may be optionally substituted or unsubstituted, and when substituted, the substituents are preferably one or more of the following groups independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxy, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkyloxy, heterocycloalkyloxy, cycloalkylthio, heterocycloalkylthio, oxo, carboxyl or carboxylate.
[0180] The term "aryl" refers to a 6- to 14-membered all-carbon monocyclic or fused polycyclic (i.e., rings that share adjacent pairs of carbon atoms) group having a conjugated π electron system, preferably 6- to 10-membered, such as phenyl and naphthyl. More preferably phenyl. The aryl ring may be fused to a heteroaryl, heterocyclyl or cycloalkyl ring, wherein the ring connected to the parent structure is an aryl ring, non-limiting examples of which include:
[0181]
[0182] The aryl group may be substituted or unsubstituted, and when substituted, the substituent is preferably one or more of the following groups independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxy, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkyloxy, heterocycloalkyloxy, cycloalkylthio, heterocycloalkylthio, carboxyl or carboxylate.
[0183] The term "heteroaryl" refers to a heteroaromatic system containing 1 to 4 heteroatoms and 5 to 14 ring atoms, wherein the heteroatoms are selected from oxygen, sulfur and nitrogen. The heteroaryl group is preferably 5 to 10 members, containing 1 to 3 heteroatoms; more preferably 5 or 6 members, containing 1 to 2 heteroatoms; preferably, for example, imidazolyl, furanyl, thienyl, thiazolyl, pyrazolyl, oxazolyl, pyrrolyl, tetrazolyl, pyridyl, pyrimidyl, thiadiazole, pyrazinyl, etc., preferably imidazolyl, thiazolyl, pyrazolyl or pyrimidyl, thiazolyl; more preferably pyrazolyl or thiazolyl. The heteroaryl ring can be fused to an aryl, heterocyclyl or cycloalkyl ring, wherein the ring connected to the parent structure is a heteroaryl ring, non-limiting examples of which include:
[0184]
[0185] The heteroaryl group may be optionally substituted or unsubstituted, and when substituted, the substituents are preferably one or more groups independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxy, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkyloxy, heterocycloalkyloxy, cycloalkylthio, heterocycloalkylthio, carboxyl or carboxylate.
[0186] The term "alkoxy" refers to-O-(alkyl) and-O-(unsubstituted cycloalkyl), wherein the definition of alkyl is as described above. The non-limiting examples of alkoxy include: methoxy, ethoxy, propoxy, butoxy, cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy. Alkoxy can be optionally substituted or unsubstituted, and when substituted, substituents are preferably one or more of the following groups, which are independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, sulfhydryl, hydroxyl, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkyloxy, heterocycloalkyloxy, cycloalkylthio, heterocycloalkylthio, carboxyl or carboxylate.
[0187] The term "haloalkyl" refers to an alkyl group substituted with one or more halogens, wherein alkyl is as defined above.
[0188] The term "haloalkoxy" refers to an alkoxy group substituted with one or more halogens, wherein alkoxy is as defined above.
[0189] The term "hydroxy" refers to an -OH group.
[0190] The term "halogen" refers to fluorine, chlorine, bromine or iodine.
[0191] The term "amino" refers to -NH2.
[0192] The term "cyano" refers to -CN.
[0193] The term "nitro" refers to -NO2.
[0194] The term "oxo" refers to =0.
[0195] The term "carboxy" refers to -C(O)OH.
[0196] The term "thiol" refers to -SH.
[0197] The term "ester group" refers to -C(O)O(alkyl) or -C(O)O(cycloalkyl), wherein alkyl and cycloalkyl are as defined above.
[0198] The term "acyl" refers to a compound containing a -C(O)R group, wherein R is alkyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl.
[0199] "Optional" or "optionally" means that the subsequently described event or circumstance may but need not occur, and the description includes instances where the event or circumstance occurs or does not occur. For example, "a heterocyclic group optionally substituted with an alkyl group" means that an alkyl group may but need not be present, and the description includes instances where the heterocyclic group is substituted with an alkyl group and instances where the heterocyclic group is not substituted with an alkyl group.
[0200] "Substituted" means that one or more hydrogen atoms, preferably up to 5, more preferably 1 to 3 hydrogen atoms in the group are replaced independently of each other by a corresponding number of substituents. It goes without saying that the substituents are only in their possible chemical positions, and the skilled person can determine (by experiment or theory) possible or impossible substitutions without undue effort. For example, amino or hydroxy groups with free hydrogens may be unstable when combined with carbon atoms with unsaturated (e.g. olefinic) bonds.
[0201] "Pharmaceutical composition" means a mixture containing one or more compounds described herein or their physiologically / pharmaceutically acceptable salts or prodrugs and other chemical components, as well as other components such as physiologically / pharmaceutically acceptable carriers and excipients. The purpose of a pharmaceutical composition is to facilitate administration to an organism, facilitate the absorption of the active ingredient, and thus exert biological activity.
[0202] "Pharmaceutically acceptable salts" refer to salts of the compounds of the present invention, which are safe and effective when used in mammals and have the desired biological activity.
[0203] Synthesis method of the compound of the present invention
[0204] In order to achieve the purpose of the present invention, the present invention adopts the following synthesis scheme to prepare the compound of general formula (I) of the present invention.
[0205] When X is -O-, Y 1 and Y 2 When is O, L is -CH2-, ring C is a piperidine ring, and ring B is a chloropyrazole ring, the compound of general formula (I) is synthesized according to Scheme 1:
[0206]
[0207] Solution 1
[0208] Step 1: In the presence of a catalyst, compound Ia is reacted with amino-protected serine methyl ester to obtain compound Ib, wherein the catalyst is preferably triphenylphosphine and DIAD, and the protecting group is preferably Boc and Trt;
[0209] Step 2: In the presence of a catalyst, subjecting compound Ib to a hydrogenation reaction to obtain compound Ic, wherein the catalyst is preferably palladium on carbon;
[0210] Step 3: In the presence of a catalyst, compound Ic undergoes an intramolecular ring-closure reaction to obtain compound Id, wherein the catalyst is preferably trimethylaluminum;
[0211] Step 4: Under alkaline conditions, compound Id is reacted with R 5 I is reacted to obtain compound Ie, wherein the alkaline condition is preferably cesium carbonate;
[0212] Step 5: Under acidic conditions, compound Ie is subjected to a deprotection reaction to obtain compound If, wherein the acidic conditions are preferably trifluoroacetic acid;
[0213] Step 6: Under alkaline conditions, diethyl butynedioate is reacted with a hydrazine compound Ig to obtain a compound Ih, wherein the alkaline condition is preferably potassium carbonate;
[0214] Step 7: In the presence of a catalyst, compound Ih is subjected to a Vilsmeier-Hake reaction and chlorinated to obtain compound Ii, wherein the catalyst is preferably DMF and phosphorus oxychloride;
[0215] Step 8: Under alkaline conditions, reacting compound Ii with a wittig reagent to obtain compound Ij, wherein the alkaline conditions are preferably potassium tert-butoxide;
[0216] Step 9: Under acidic conditions, hydrolyzing compound Ij to obtain compound Ik, wherein the acidic conditions are preferably hydrochloric acid;
[0217] Step 10: Under the condition of a catalyst, compound Ik and compound If are subjected to a reductive amination reaction to obtain compound Il, wherein the catalyst is preferably a 2-methylpyridine borane complex;
[0218] Step 11: In the presence of a catalyst, subjecting compound I1 to an intramolecular ring-closing reaction to obtain a compound of formula (I), wherein the catalyst is preferably trimethylaluminum;
[0219] Among them, Z 1 , Z 2 , Ring A, R 1, R 2 , R 3 , R 4 , R 5 As defined in general formula (I). DETAILED DESCRIPTION
[0220] The compounds of the present invention and their preparation are further understood by way of examples, which illustrate some methods of preparing or using the compounds. However, it is to be understood that these examples do not limit the present invention. Variations of the present invention now known or further developed are considered to fall within the scope of the invention described herein and claimed.
[0221] The compounds of the present invention are prepared using convenient starting materials and common preparation steps. The present invention provides typical or preferred reaction conditions, such as reaction temperature, time, solvent, pressure, and molar ratio of reactants. However, unless otherwise specified, other reaction conditions can also be adopted. The optimized conditions may change with the use of specific reactants or solvents, but in general, the reaction optimized steps and conditions can be determined.
[0222] In addition, some protecting groups may be used in the present invention to protect certain functional groups from unnecessary reactions. Protecting groups suitable for various functional groups and their protection or deprotection conditions are widely known to those skilled in the art. For example, TW Greene and GM Wuts's "Protective Groups in Organic Preparations" (3rd edition, Wiley, New York, 1999 and references therein) describes in detail the protection or deprotection of a large number of protecting groups.
[0223] The separation and purification of compounds and intermediates can be carried out by appropriate methods and steps according to specific needs, such as filtration, extraction, distillation, crystallization, column chromatography, preparative thin layer plate chromatography, preparative high performance liquid chromatography or a combination of the above methods. The specific use method can refer to the examples described in the present invention. Of course, other similar separation and purification means can also be adopted. Conventional methods (including physical constants and spectral data) can be used to characterize them.
[0224] The structures of the compounds were determined by nuclear magnetic resonance (NMR) and / or mass spectrometry (MS). -6 The unit of (ppm) is given. NMR measurements were performed using a Brukerdps 300 nuclear magnetic spectrometer, the measurement solvents were deuterated dimethyl sulfoxide (DMSO-d6), deuterated chloroform (CDCl3), deuterated methanol (CD3OD), and the internal standard was tetramethylsilane (TMS).
[0225] MS was measured using LC (Waters 2695) / MS (Quattro Premier xE) mass spectrometer (manufacturer: Waters) (Photodiode Array Detector).
[0226] The preparative liquid chromatography method used an LC6000 high performance liquid chromatograph (manufacturer: Chuangxin Tongheng), the chromatographic column was Daisogel C18 10 μm 100A (30 mm×250 mm), and the mobile phase was acetonitrile / water.
[0227] Thin layer chromatography (TLC) used Qingdao Ocean Chemical GF254 silica gel plate. The silica gel plate used in reaction monitoring thin layer chromatography adopted a specification of 0.20 mm to 0.25 mm, and the silica gel plate used in separation and purification thin layer chromatography adopted a specification of 0.5 mm.
[0228] Silica gel column chromatography uses Qingdao marine silica gel 100-200 mesh, 200-300 mesh and 300-400 mesh silica gel as the carrier.
[0229] The known starting materials of the present invention can be synthesized by methods known in the art, or can be purchased from online shopping malls, Beijing Coupling, Sigma, Bailingwei, Yishiming, Shanghai Shuya, Shanghai Inokai, Anaiji Chemical, Shanghai Bid, etc.
[0230] Unless otherwise specified in the examples, all reactions were carried out under a nitrogen atmosphere.
[0231] Argon atmosphere or nitrogen atmosphere means that the reaction bottle is connected to an argon or nitrogen balloon with a capacity of about 1L.
[0232] Reaction solvent, organic solvent or inert solvent are each expressed as the solvent used that does not participate in the reaction under the described reaction conditions, including, for example, benzene, toluene, acetonitrile, tetrahydrofuran (THF), dimethylformamide (DMF), chloroform, dichloromethane, ether, methanol, nitrogen-methylpyrrolidone (NMP), pyridine, etc. Unless otherwise specified in the examples, the solution refers to an aqueous solution.
[0233] The chemical reactions described in the present invention are generally carried out under normal pressure. The reaction temperature is between -78°C and 200°C. The reaction time and conditions are, for example, between -78°C and 200°C at one atmosphere, and are completed within about 1 to 24 hours. If the reaction is left overnight, the reaction time is generally 16 hours. In the embodiments, unless otherwise specified, the reaction temperature is room temperature, which is 20°C to 30°C.
[0234] The reaction progress in the examples was monitored by thin layer chromatography (TLC), and the developing solvent systems used in the reaction were: A: dichloromethane and methanol system, B: petroleum ether and ethyl acetate system, C: acetone, and the volume ratio of the solvent was adjusted according to the polarity of the compound.
[0235] The eluent system of column chromatography and the developing solvent system of thin layer chromatography used for purifying compounds include: A: dichloromethane and methanol system, B: petroleum ether and ethyl acetate system. The volume ratio of the solvent is adjusted according to the polarity of the compound, and a small amount of alkaline or acidic reagents such as triethylamine and trifluoroacetic acid can also be added for adjustment.
[0236] Unless otherwise defined, all professional and scientific terms used herein have the same meaning as those familiar to those skilled in the art. In addition, any method and material similar or equivalent to the described content can be applied to the method of the present invention.
[0237] Example
[0238] Example 1: Preparation of (S)-3-(2-benzyl-3-chloro-7-oxo-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)-5-methyl-2,3,7,8,9,10-hexahydronaphtho[2,3-b][1,4]oxazol-4(5H)-one (1).
[0239]
[0240]
[0241] Step 1: Preparation of 3-nitro-5,6,7,8-tetrahydronaphthalen-2-ol (1a)
[0242] At 0°C, 5,6,7,8-tetrahydronaphthalene-2-ol (10.00 g, 67.5 mmol) was added to a mixed solvent of chloroform (80 mL) and acetic acid (80 mL), stirred for 10 minutes, and then nitric acid (5.20 g, 81 mmol) was slowly added dropwise. The reaction solution was warmed to room temperature, stirred for half an hour, poured into crushed ice, extracted with dichloromethane (50 mL), and the organic phase was concentrated under reduced pressure. The residue was separated and purified by silica gel column chromatography (mobile phase: PE / EA=20:1-10:1) to obtain 4.00 g of the title compound as a yellow solid, with a yield of 30.7%.
[0243] LC-MS: m / z 194.24 [M+H] + .
[0244] Step 2: Preparation of (3-nitro-5,6,7,8-tetrahydronaphthalen-2-yl)-N-trityl-L-serine methyl ester (1b)
[0245] Dissolve triphenylphosphine (6.56 g, 25 mmol) in 30 mL THF, add DIAD (5.04 g, 25 mmol) dropwise at 0°C under nitrogen atmosphere, continue stirring for 10 minutes, add L-Trt-serine methyl ester (8.80 g, 22.8 mmol), continue stirring for 10 minutes, add 3-nitro-5,6,7,8-tetrahydronaphthalen-2-ol (4.00 g, 20.8 mmol), stir at room temperature overnight, concentrate under reduced pressure, and separate and purify the residue by silica gel column chromatography (mobile phase: DCM / MeOH=150:1-100:1) to obtain 3.90 g of the title compound as a light yellow solid, yield: 35.7%.
[0246] LC-MS: m / z 537.74 [M+H] + .
[0247] Step 3: Preparation of (3-nitro-5,6,7,8-tetrahydronaphthalen-2-yl)-L-serine methyl ester (1c)
[0248] Dissolve (3-nitro-5,6,7,8-tetrahydronaphthalen-2-yl)-N-trityl-L-serine methyl ester (3.90 g, 7.3 mmol) in 10 mL of saturated hydrochloric acid ethyl acetate solution, stir at room temperature for 1 hour and filter. Adjust the pH of the filtrate to 10 and extract with ethyl acetate (20 mL). The organic phase is concentrated under reduced pressure to obtain 1.80 g of the title compound as a white solid, with a yield of 83.8%.
[0249] LC-MS: m / z 295.41 [M+H] + .
[0250] Step 4: Preparation of N-(tert-butoxycarbonyl)-O-(3-nitro-5,6,7,8-tetrahydronaphthalen-2-yl)-L-serine methyl ester (1d)
[0251] Dissolve (3-nitro-5,6,7,8-tetrahydronaphthalen-2-yl)-L-serine methyl ester (1.80 g, 6 mmol) in 10 mL of dichloromethane, add DIPEA (1.55 g, 12 mmol), and then add Boc anhydride (2.60 g, 12 mmol) in batches. After stirring at room temperature for 1 hour, wash with water (20 mL), dry the organic phase with anhydrous sodium sulfate, filter, and concentrate the filtrate under reduced pressure to obtain 2.30 g of the title compound as a yellow solid, with a yield of 97.3%.
[0252] LC-MS: m / z 395.76 [M+H] + .
[0253] Step 5: Preparation of O-(3-amino-5,6,7,8-tetrahydronaphthalen-2-yl)-N-(tert-butoxycarbonyl)-L-serine methyl ester (1e)
[0254] At room temperature, N-(tert-butoxycarbonyl)-O-(3-nitro-5,6,7,8-tetrahydronaphthalen-2-yl)-L-serine methyl ester (2.3 g, 5.84 mmol) was dissolved in methanol (15 mL), palladium carbon (100 mg) was added, and the mixture was stirred for 3 hours under a hydrogen atmosphere. The mixture was filtered and the filtrate was concentrated under reduced pressure to give 2.1 g of the title compound as a brown oil. The yield was 98.8%.
[0255] LC-MS: m / z 365.20 [M+H] + .
[0256] Step 6: Preparation of tert-butyl (S)-(4-oxo-2,3,4,5,7,8,9,10-octahydronaphtho[2,3-b][1,4]oxazepin-3-yl)carbamate (1f)
[0257] Dissolve O-(3-amino-5,6,7,8-tetrahydronaphthalen-2-yl)-N-(tert-butoxycarbonyl)-L-serine methyl ester (2.1 g, 5.8 mmol) in 20 mL of chloroform, and add 2 M trimethylaluminum toluene solution (3 mL) dropwise at 0°C under nitrogen atmosphere. Heat the mixture to 60°C under nitrogen atmosphere and stir for 2 hours. Then, add 10 mL of ethanol to the reaction solution, continue stirring for 10 minutes, filter out insoluble matter, and concentrate the filtrate under reduced pressure. The residue is separated and purified by silica gel column chromatography (mobile phase PE / EA=10:1) to obtain 1.2 g of the title compound as a white solid, with a yield of 62.3%.
[0258] LC-MS: m / z 332.17 [M+H] + .
[0259] Step 7: Preparation of tert-butyl (S)-(5-methyl-4-oxo-2,3,4,5,7,8,9,10-octahydronaphtho[2,3-b][1,4]oxazepin-3-yl)carbamate (1 g)
[0260] At room temperature, (S)-(4-oxo-2,3,4,5,7,8,9,10-octahydronaphtho[2,3-b][1,4]oxazepine-3-yl)carbamic acid tert-butyl ester (0.8 g, 2.4 mmol) and cesium carbonate (1.7 g, 5.28 mmol) were dissolved in 10 mL of DMF. Methyl iodide (0.16 mL, 2.4 mmol) was added dropwise thereto and stirred for 2 hours. Then 30 mL of water and 30 mL of EA were added, the organic layer was washed with 20 mL of saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain 470 mg of the title compound as a light yellow solid with a yield of 56.7%.
[0261] LC-MS: m / z 347.19 [M+H] + .
[0262] Step 8: Preparation of (S)-3-amino-5-methyl-2,3,7,8,9,10-hexahydronaphtho[2,3-b][1,4]oxazepin-4(5H)-one (1h)
[0263] At room temperature, tert-butyl (S)-(5-methyl-4-oxo-2,3,4,5,7,8,9,10-octahydronaphtho[2,3-b][1,4]oxazepin-3-yl)carbamate (0.47 g, 1.36 mmol) was dissolved in 5 mL of TFA. After stirring for 1 hour, 15 mL of saturated sodium bicarbonate solution and 20 mL of EA were added. The organic phase was concentrated under reduced pressure and the residue was separated by TLC (developing solvent PE / EA=10:1) to give 320 mg of the title compound as an off-white solid. Yield: 95.6%.
[0264] LC-MS: m / z 247.14 [M+H] + .
[0265] Step 9: Preparation of ethyl 1-benzyl-5-hydroxy-1H-pyrazole-3-carboxylate (1i)
[0266] At 0°C, diethyl butynedioate (4.4 g, 25.6 mmol), benzylhydrazine dihydrochloride (5 g, 25.6 mmol) and anhydrous potassium carbonate (8.8 g, 64 mmol) were added to 160 mL of anhydrous ethanol and heated under reflux with stirring overnight. The reaction solution was cooled to room temperature and the reaction solution was continued to stir for 5 hours. 6N hydrochloric acid was added to adjust the pH value to 3. 300 mL of water and 150 mL of ethyl acetate were added, the organic layer was washed with 100 mL of saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was slurried with 10 mL of acetonitrile to obtain 2.2 g of the title compound as a yellow solid with a yield of 35%.
[0267] LC-MS: m / z 247.10 [M+H]+ .
[0268] Step 10: Preparation of ethyl 1-benzyl-5-chloro-4-formyl-1H-pyrazole-3-carboxylate (1j)
[0269] At room temperature, add 1-benzyl-5-hydroxy-1H-pyrazole-3-carboxylic acid ethyl ester (0.5 g, 2.1 mmol) to DMF 0.65 mL, add phosphorus oxychloride (1.6 mL, 16 mmol) dropwise, heat to 90 ° C and stir for 4 hours. Slowly pour the reaction solution into an ice-saturated sodium bicarbonate solution, add 30 mL of ethyl acetate, wash the organic phase with 20 mL of saturated brine, dry over anhydrous sodium sulfate, filter, and concentrate the filtrate under reduced pressure. The residue is separated and purified by silica gel column chromatography (mobile phase: PE / EA=10:1-5:1) to obtain 300 mg of the title compound as a white solid, with a yield of 48.9%.
[0270] LC-MS: m / z 293.06 [M+H] + .
[0271] Step 11: Preparation of ethyl 1-benzyl-5-chloro-4-(2-methoxyvinyl)-1H-pyrazole-3-carboxylate (1k)
[0272] At room temperature, (methoxymethyl) triphenylphosphonium chloride (1.6 g, 4.8 mmol) was dissolved in 20 mL of anhydrous tetrahydrofuran. At 0°C, a solution of potassium tert-butoxide (0.5 g, 4.4 mmol) dissolved in 10 mL of anhydrous tetrahydrofuran was added dropwise. After stirring for 10 minutes, a solution of 1-benzyl-5-chloro-4-formyl-1H-pyrazole-3-carboxylic acid ethyl ester (0.3 g, 1.1 mmol) in 10 mL of anhydrous tetrahydrofuran was added dropwise. Stirring was continued for 30 minutes, then the mixture was warmed to room temperature and stirred overnight. 60 mL of water and 40 mL of ethyl acetate were added to the reaction solution, the organic phase was washed with 50 mL of saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was separated and purified by silica gel column chromatography (mobile phase: PE / EA=5:1-2:1) to obtain 200 mg of the title compound as a yellow solid with a yield of 56.8%.
[0273] LC-MS: m / z 321.09 [M+H] + .
[0274] Step 12: Preparation of ethyl 1-benzyl-5-chloro-4-(2-oxoethyl)-1H-pyrazole-3-carboxylate (11)
[0275] At room temperature, dissolve 1-benzyl-5-chloro-4-(2-methoxyvinyl)-1H-pyrazole-3-carboxylic acid ethyl ester (0.2 g, 0.63 mmol) in 10 mL of THF, add 2 mL of 6N hydrochloric acid, and heat to 60°C. Stir for 30 minutes. Pour the reaction solution into 20 mL of saturated sodium bicarbonate solution, add 30 mL of ethyl acetate, wash the organic phase with 20 mL of saturated brine, dry over anhydrous sodium sulfate, filter, and concentrate the filtrate under reduced pressure to obtain 190 mg of the title compound as a colorless oil, with a yield of 98.6%.
[0276] LC-MS: m / z 307.08 [M+H] + .
[0277] Step 13: Preparation of (S)-1-benzyl-5-chloro-4-(2-((5-methyl-4-oxo-2,3,4,5,7,8,9,10-octahydronaphtho[2,3-b][1,4]oxazepin-3-yl)amino)ethyl)-1H-pyrazole-3-carboxylic acid ethyl ester (1m)
[0278] At room temperature, 1-benzyl-5-chloro-4-(2-oxoethyl)-1H-pyrazole-3-carboxylic acid ethyl ester (0.19 g, 0.6 mmol) and (S)-3-amino-5-methyl-2,3,7,8,9,10-hexahydronaphtho[2,3-b][1,4]oxazepine-4(5H)-one (1h) (0.15 g, 0.6 mmol) were dissolved in 15 mL of methanol, 1 mL of acetic acid was added, and after stirring for 10 minutes, 2-methylpyridine borane complex (0.1 g, 0.84 mmol) was added, and stirring was continued for 1 hour. 20 mL of water and 30 mL of ethyl acetate were added to the reaction solution, and the organic phase was washed with 20 mL of saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was separated by TLC (PE / EA=1:1) to obtain 210 mg of the title compound as a yellow solid, with a yield of 65.3%.
[0279] LC-MS: m / z 537.22 [M+H] + .
[0280] Step 14: Preparation of (S)-3-(2-benzyl-3-chloro-7-oxo-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)-5-methyl-2,3,7,8,9,10-hexahydronaphtho[2,3-b][1,4]oxazepin-4(5H)-one (Compound 1)
[0281] At room temperature, (S)-1-benzyl-5-chloro-4-(2-((5-methyl-4-oxo-2,3,4,5,7,8,9,10-octahydronaphtho[2,3-b][1,4]oxazepin-3-yl)amino)ethyl)-1H-pyrazole-3-carboxylic acid ethyl ester (0.21 g, 0.4 mmol) was dissolved in 5 mL of toluene. Under a nitrogen atmosphere, 0.8 mL of trimethylaluminum n-hexane solution was added. The temperature was raised to 90°C and stirred for 2 hours. 30 mL of water and 30 mL of ethyl acetate were added to the reaction solution, and the organic phase was washed with 20 mL of saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was separated by preparative liquid chromatography (chromatographic column model: Daisogei 30mm*250mm, C18, 10um100A, mobile phase: acetonitrile / water, gradient: 30%-80%) to obtain 55 mg of the title compound as a white solid, with a yield of 28.1%.
[0282] LC-MS: m / z 491.18 [M+H] + .
[0283] 1 HNMR (300MHz, DMSO-d6) δ7.38-7.17 (m, 6H), 6.92 (s, 1H), 5.55 (dd, J=11.8, 7.9Hz, 1H), 5.43 (s, 2H), 4.81-4.71 (m, 1H), 4.30-4.20 (m, 1H), 4.01 (d, J=7.0Hz, 1H), 3.61 (s, 1H), 3.26 (s, 3H), 2.73 (s, 6H), 1.74 (td, J=6.3, 3.4Hz, 4H).
[0284] Example 2: Preparation of (S)-8-(2-benzyl-3-chloro-7-oxo-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)-10-methyl-2,3,7,8-tetrahydro-[1,4]dioxino[2′3′:4,5]benzo[1,2-b][1,4]oxazepine-9(10H)-one (2).
[0285]
[0286] The title compound 2 was prepared in the same manner as in Example 1, except that 2,2-dihydrobenzo[b][1,4]dioxin-6-ol was used instead of 5,6,7,8-tetrahydronaphthalen-2-ol in step 1.
[0287] LC-MS: m / z 495.14 [M+H] + .
[0288] 1H NMR (300MHz, DMSO-d6) δ7.35-7.32 (m, 3H), 7.19-7.16 (m, 2H), 7.07 (s, 1H), 6.79 (s, 1H), 5.58-5.56 (m, 1H), 5.45 (s, 2H), 4.8 1-4.67 (m, 1H), 4.31-4.28 (m, 5H), 4.10-3.95 (m, 1H), 3.71-3.55 (m, 1H), 3.24 (s, 3H), 2.92-2.74 (m, 1H), 2.74-2.63 (m, 1H).
[0289] Example 3: Preparation of (S)-3-(2-benzyl-3-chloro-7-oxo-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)-1,7-dimethyl-1,3,4,7,9,10-hexahydro-[1,4]oxazepino[3,2-g]quinoline-2,8-dione (3)
[0290]
[0291] The title compound 3 was prepared in the same manner as in Example 1, except that 7-hydroxy-1-methyl-3,4-dihydroquinolin-2(1H)-one was used instead of 5,6,7,8-tetrahydronaphthalen-2-ol in step 1.
[0292] LC-MS: m / z 520.99 [M+H] + .
[0293] 1 H NMR (400MHz, DMSO-d6) δ7.44-7.29 (m, 4H), 7.21 (d, 2H), 7.00 (s, 1H), 5.67-5.54 (m, 1H), 5.45 (s, 2H), 4.85 (t, 1H), 4.45- 4.32 (m, 1H), 4.11-3.98 (m, 1H), 3.73-3.58 (m, 1H), 3.28 (d, 6H), 2.96-2.89 (m, 2H), 2.85-2.78 (m, 1H), 2.73-2.59 (m, 3H).
[0294] Example 4: Preparation of (S)-8-(2-benzyl-3-chloro-7-oxo-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)-4,10-dimethyl-2,3,4,7,8,10-hexahydro-9H-[1,4]oxazino[2′,3′:4,5]benzo[1,2-b][1,4]oxazepin-9-one (4)
[0295]
[0296]
[0297] Step 1: Preparation of 6-methoxy-2H-benzo[b][1,4]oxazin-3-(4H)-one (4a)
[0298] At room temperature, 2-amino-4-methoxyphenol (1.80 g, 12.9 mmol) was dissolved in acetonitrile (30 mL), potassium carbonate (5.36 g, 38.8 mmol) was added, chloroacetyl chloride (2.19 g, 19.4 mmol) was added at 0°C, and the mixture was stirred at 80°C overnight. 20 mL of water was added to quench the mixture, EA was extracted (20 mL x 3), the mixture was washed with saturated brine (20 mL x 1), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was separated and purified by silica gel column chromatography (mobile phase: PE / EA = 100: 1-5: 1) to obtain 2.49 g of the title compound as a brown solid (crude product).
[0299] LC-MS: m / z 180.06 [M+H] + .
[0300] Step 2: Preparation of 6-methoxy-7-nitro-2H-benzo[b][1,4]oxazin-3(4H)-one (4b)
[0301] 6-Methoxy-2H-benzo[b][1,4]oxazin-3(4H)-one (12.0 g, 67.0 mmol) was dissolved in AcOH (36 ml) at room temperature. HNO3 (67%, 12 ml) was slowly added at 0°C and stirred for 30 minutes. The reaction solution was quenched with ice water, filtered and the solid was collected and dried to obtain 9 g of the title compound as a green solid with a yield of 60%.
[0302] LC-MS: m / z 225.04 [M+H] + .
[0303] Step 3: Preparation of 6-methoxy-7-nitro-3,4-dihydro-2H-benzo[b][1,4]oxazine (4c)
[0304] 6-Methoxy-7-nitro-2H-benzo[b][1,4]oxazin-3(4H)-one (8.00 g, 35.4 mmol) was dissolved in THF (150 ml) at room temperature. BH3-THF (35.4 ml, 70.8 mmol, 2 M) was added at 0°C under nitrogen atmosphere. The reaction solution was heated to 65°C and stirred for 1 hour. The reaction solution was quenched with water and extracted with EA (50 mL x 3). The combined organic phases were washed with saturated NaCl solution, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was separated and purified by silica gel column chromatography (mobile phase: PE / EA=2:1) to obtain 7.5 g of the title compound as a green solid with a yield of 99%.
[0305] LC-MS: m / z 211.06 [M+H] + .
[0306] Step 4: Preparation of 6-methoxy-4-methyl-7-nitro-3,4-dihydro-2H-benzo[b][1,4]oxazine (4d)
[0307] At room temperature, 6-methoxy-7-nitro-3,4-dihydro-2H-benzo[b][1,4]oxazine (4.40 g, 20.9 mmol) was dissolved in DMF (70 ml). Under nitrogen atmosphere, at 0°C, NaH (1.26 g, 30.4 mmol, 60%) was added in batches, stirred for 0.5 hours, and iodomethane (5.95 g, 41.9 mmol) was added. The reaction solution was warmed to room temperature and stirred overnight. The reaction solution was quenched with water, extracted with EA (80 mL x 3), the combined organic phases were washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was separated and purified by silica gel column chromatography (mobile phase: PE / EA = 2:1) to obtain 4 g of the title compound as a light brown solid with a yield of 84.7%.
[0308] LC-MS: m / z 225.08 [M+H] + .
[0309] Step 5: Preparation of 4-methyl-7-nitro-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-ol (4e)
[0310] 6-Methoxy-4-methyl-7-nitro-3,4-dihydro-2H-benzo[b][1,4]oxazine (3.80 g, 16.9 mmol) was dissolved in DCM (100 mL) at room temperature. Under nitrogen atmosphere, a DCM solution of BBr3 (50.89 ml, 50.89 mmol, 1 M) was added dropwise at -78°C. The mixture was stirred at -20°C for 2 hours. Water was added at -20°C to quench the mixture, and the mixture was extracted with DCM (50 mL x 3), dried over anhydrous Na2SO4, filtered, and the filtrate was concentrated under reduced pressure. The residue was separated and purified by silica gel column chromatography (mobile phase: PE / EA=1:1) to obtain 1.5 g of the title compound as a brown solid in a yield of 42.2%.
[0311] LC-MS: m / z 211.06 [M+H] + .
[0312] The other steps are the same as the preparation method of Example 1, except that 4-methyl-7-nitro-3,4-dihydro-2H-benzo[b][1,4]oxazine-6-ol (4e) is used instead of 3-nitro-5,6,7,8-tetrahydronaphthalen-2-ol (1a) in step 2 to obtain the title compound 4.
[0313] LC-MS: m / z 508.17 [M+H] + .
[0314] 1H NMR (400MHz, DMSO-d6) δ7.34-7.30(m, 4H), 7.28(s, 1H), 6.64(s, 1H), 6.47(s, 1H), 5.96-5.91(m, 1H), 5.41(s , 2H), 4.60-4.57(m, 1H), 4.42-4.27(m, 5H), 3.56-3.53(m, 2H), 3.32(s, 3H), 3.12-3.04(m, 2H), 2.93(s, 3H).
[0315] Example 5: Preparation of (S)-3-(2-benzyl-3-chloro-7-oxo-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)-5-methyl-8-(2,2,2-trifluoroacetyl)-2,3,7,8,9,10-hexahydro-[1,4]oxazepino[2,3-g]isoquinolin-4(5H)-one (5)
[0316]
[0317]
[0318] Step 1: Preparation of 2,2,2-trifluoro-1-(6-methoxy-3,4-dihydroisoquinolin-2-(1H-yl)ethan-1-one (5a) 6-methoxy-1,2,3,4-tetrahydroisoquinoline hydrochloride (5.00 g, 25.0 mmol) was dissolved in DCM (100 ml) at room temperature, and TEA (7.58 g, 75.0 mmol) was added. TFAA (7.87 g, 37.5 mmol) was added to the reaction solution at 0°C under a nitrogen atmosphere, and the reaction solution was warmed to room temperature and stirred for 2 hours. The reaction was quenched with water, extracted with DCM (120 mL x 2), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was separated and purified by silica gel column chromatography (mobile phase: PE / EA=4:1) to obtain 6.5 g of the title compound as a colorless transparent liquid with a yield of 99.9%.
[0319] LC-MS: m / z 260.08 [M+H] + .
[0320] Step 2: Preparation of 2,2,2-trifluoro-1-(6-methoxy-7-nitro-3,4-dihydroisoquinolin-2-(1H)-yl)ethan-1-one (5b)
[0321] 2,2,2-Trifluoro-1-(6-methoxy-3,4-dihydroisoquinolin-2-(1H-yl)ethan-1-one (6.50 g, 25.1 mmol) was dissolved in MeCN (90 mL), and NaNO3 (2.14 g, 25.1 mmol) was added. TFAA (8.44 g, 40.2 mmol) was added dropwise to the reaction solution at 0°C under a nitrogen atmosphere, and the reaction solution was warmed to room temperature and stirred overnight. The reaction solution was quenched with water, extracted with EA (120 mL x 2), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was separated and purified by silica gel column chromatography (mobile phase: PE / EA=3:1) to obtain 4 g of the title compound as a light yellow solid with a yield of 52.4%.
[0322] LC-MS: m / z 305.07 [M+H] + .
[0323] Step 3: Preparation of 2,2,2-trifluoro-1-(6-hydroxy-7-nitro-3,4-dihydroisoquinolin-2-(1H)-yl)ethan-1-one (5c)
[0324] 2,2,2-Trifluoro-1-(6-methoxy-7-nitro-3,4-dihydroisoquinolin-2-(1H)-yl)ethan-1-one (3.00 g, 9.87 mmol) was dissolved in DCM (50 ml). BBr3 (4.87 g, 19.7 mmol) was added dropwise to the reaction solution at 0°C under a nitrogen atmosphere, and stirring was continued for 1.5 hours. Water was added to quench the mixture, and DCM (60 mL x 2) was used for extraction. The combined organic phases were washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain 2.7 g of the title compound as a light yellow solid oil with a yield of 94.4%.
[0325] LC-MS: m / z 291.05 [M+H] + .
[0326] Step 4: Preparation of O-(7-nitro-2-(2,2,2-trifluoroacetyl)-1,2,3,4-tetrahydroisoquinolin-6-yl)-N-trityl-L-serine methyl ester (5d)
[0327] At room temperature, 2,2,2-trifluoro-1-(6-hydroxy-7-nitro-3,4-dihydroisoquinolin-2-(1H)-yl)ethan-1-one (2.70 g, 9.31 mmol) and trityl-L-serine methyl ester (5.04 g, 14.0 mmol) were dissolved in 50 mL of THF, and triphenylphosphine (4.90 g, 18.6 mmol) was added. Under nitrogen atmosphere, diisopropyl azodicarboxylate (DIAD) (3.76 g, 18.6 mmol) was added to the reaction solution in an ice bath. The reaction solution was warmed to room temperature and stirred overnight. Water was added to dilute, extracted with EA (50 mL x 2), washed with saturated NaCl (50 mL x 2), dried over anhydrous Na2SO4, filtered, and the filtrate was concentrated under reduced pressure. 5 g of the title compound was obtained as a brown oil, with a yield of 84.7%.
[0328] LC-MS: m / z 634.62 [M+H] + .
[0329] Step 5: Preparation of O-(7-nitro-2-(2,2,2-trifluoroacetyl)-1,2,3,4-tetrahydroisoquinolin-6-yl)-L-serine methyl ester (5e)
[0330] At room temperature, O-(7-nitro-2-(2,2,2-trifluoroacetyl)-1,2,3,4-tetrahydroisoquinolin-6-yl)-N-trityl-L-serine methyl ester (5.00 g, 7.89 mmol) was dissolved in 60 mL of DCM, and a dioxane solution of HCl (15 ml) was added to the reaction solution. Stir overnight at room temperature. Saturated NaHCO3 solution was added to adjust the pH value to alkaline, and the mixture was extracted with EA (90 mL x 3), washed with saturated NaCl (150 mL x 2), dried over anhydrous Na2SO4, filtered, and the filtrate was concentrated under reduced pressure. 3.6 g of the title compound was obtained as a brown oil with a yield of 99%.
[0331] LC-MS: m / z 392.30 [M+H] + .
[0332] Step 6: Preparation of N-(tert-butoxycarbonyl)-O-(7-nitro-2-(2,2,2-trifluoroacetyl)-1,2,3,4-tetrahydroisoquinolin-6-yl)-L-serine methyl ester (5f)
[0333] At room temperature, O-(7-nitro-2-(2,2,2-trifluoroacetyl)-1,2,3,4-tetrahydroisoquinolin-6-yl)-L-serine methyl ester (3.64 g, 9.31 mmol) was dissolved in DCM (50 ml), and DIEA (3.60 g, 27.9 mmol) and Boc2O (3.05 g, 14.0 mmol) were added to the reaction solution. Stir overnight at room temperature. Dilute with water, extract with DCM (3 x 60 ml), dry over anhydrous sodium sulfate, filter, concentrate the filtrate under reduced pressure, and separate and purify the residue by silica gel column chromatography (mobile phase: PE / EA=2:1) to obtain 4.5 g of the title compound as a yellow solid, with a yield of 98%.
[0334] LC-MS: m / z 492.42 [M+H] + .
[0335] Step 7: Preparation of O-(7-amino-2-(2,2,2-trifluoroacetyl)-1,2,3,4-tetrahydroisoquinolin-6-yl)-N-(tert-butoxycarbonyl)-L-serine methyl ester (5 g)
[0336] At room temperature, N-(tert-butoxycarbonyl)-O-(7-nitro-2-(2,2,2-trifluoroacetyl)-1,2,3,4-tetrahydroisoquinolin-6-yl)-L-serine methyl ester (4.50 g, 9.16 mmol) was dissolved in 80 mL of EA, and Pd / C (10 wt%, 1 g) was added to the reaction solution. The mixture was stirred overnight at room temperature under a hydrogen atmosphere. The reaction solution was filtered through diatomaceous earth, and the filter cake was washed with EA and MeOH. The filtrate was concentrated under reduced pressure to obtain 4 g of the title compound as a gray-black solid with a yield of 94.5%.
[0337] LC-MS: m / z 462.44 [M+H] + .
[0338] Step 8: Preparation of (S)-tert-butyl (4-oxo-8-(2,2,2-trifluoroacetyl)-2,3,4,5,7,8,9,10-octahydro-[1,4]oxazepino[2,3-g]isoquinolin-3-yl)carbamate (5h)
[0339] O-(7-amino-2-(2,2,2-trifluoroacetyl)-1,2,3,4-tetrahydroisoquinolin-6-yl)-N-(tert-butoxycarbonyl)L-serine methyl ester (500 mg, 1.08 mmol) was dissolved in chloroform (11 mL). Trimethylaluminum (1.08 ml, 2M, 2.17 mmol) was added in an ice bath under a nitrogen atmosphere. The reaction solution was warmed to room temperature and stirred for 2 h. Water was added to quench the reaction, and the mixture was filtered through celite. The filter cake was washed with DCM and extracted with DCM (2 x 50 mL). The mixture was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain 330 mg of the title compound as a yellow solid in a yield of 70.8%.
[0340] LC-MS: m / z 430.40 [M+H] + .
[0341] Step 9: Preparation of tert-butyl (S)-(5-methyl-4-oxo-8-(2,2,2-trifluoroacetyl)-2,3,4,5,7,8,9,10-octahydro-[1,4]oxazepino[2,3-g]isoquinolin-3-yl)carbamate (5i)
[0342] Dissolve (S)-(4-oxo-8-(2,2,2-trifluoroacetyl)-2,3,4,5,7,8,9,10-octahydro-[1,4]oxazepino[2,3-g]isoquinolin-3-yl)carbamic acid tert-butyl ester (330 mg, 0.769 mmol) in DMF (6 ml), add cesium carbonate (376 mg, 1.15 mmol), and under nitrogen atmosphere, add iodomethane (131 ml, 0.923 mmol). Stir at room temperature for 2 h. Dilute with water, extract with EA (2 x 15 ml), wash the organic phase with saturated brine (3 x 50 ml), dry over anhydrous sodium sulfate, filter, and concentrate the filtrate under reduced pressure. The residue is separated and purified by preparative thin layer chromatography (developing solvent: PE / EA = 4:1) to obtain 90 mg of the title compound as a light yellow solid, with a yield of 26.4%.
[0343] LC-MS: m / z 444.42 [M+H] + .
[0344] Step 10: Preparation of (S)-3-amino-5-methyl-8-(2,2,2-trifluoroacetyl)-2,3,7,8,9,10-hexahydro-[1,4]oxazepino[2,3-g]isoquinolin-4-(5H)-one (5j)
[0345] At room temperature, tert-butyl (S)-(5-methyl-4-oxo-8-(2,2,2-trifluoroacetyl)-2,3,4,5,7,8,9,10-octahydro-[1,4]oxazepine[2,3-g]isoquinolin-3-yl)carbamate (90.0 mg, 0.203 mmol) was dissolved in 4 mL DCM, and a dioxane solution of HCl (1 ml) was added to the reaction solution. Stir overnight at room temperature. Saturated NaHCO3 solution was added to adjust the pH to alkaline, and the mixture was extracted with DCM (100 mL x 3), dried over anhydrous Na2SO4, filtered, and the filtrate was concentrated under reduced pressure. 69 mg of the title compound was obtained as a brown solid, with a yield of 99%.
[0346] LC-MS: m / z 344.31 [M+H] + .
[0347] The other steps were the same as those of Example 1, except that (S)-3-amino-5-methyl-8-(2,2,2-trifluoroacetyl)-2,3,7,8,9,10-hexahydro-[1,4]oxazepin[2,3-g]isoquinolin-4-(5H)-one (5j) was used instead of (S)-3-amino-5-methyl-2,3,7,8,9,10-hexahydronaphtho[2,3-b][1,4]oxazepin-4(5H)-one (1h) in step 9 to obtain the title compound 5.
[0348] LC-MS: m / z 588.15 [M+H] + .
[0349] 1 H NMR (400MHz, DMSO-d6) δ7.47-7.45 (m, 1H), 7.37-7.27 (m, 3H), 7.20-7.17 (m, 2H), 7.10 (s, 1H), 5.58-5.53 (m, 1H), 5.42 (s, 2H), 4.84-4.78 (m, 1H), 4.32-4.27(m, 1H), 4.09-4.00(m, 1H), 3.88-3.79(m, 2H), 3.65-3.58(m, 1 H), 3.28 (s, 3H), 2.94-2.90 (m, 2H), 2.84-2.76 (m, 1H), 2.71-2.66 (m, 1H).
[0350] Example 6: Preparation of (S)-3-(2-benzyl-3-chloro-7-oxo-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)-5-methyl-2,3,7,8,9,10-hexahydro-[1,4]oxazepino[2,3-g]isoquinolin-4-(5H)-one (6)
[0351]
[0352] Step 1: Preparation of (S)-3-(2-benzyl-3-chloro-7-oxo-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)-5-methyl-2,3,7,8,9,10-hexahydro-[1,4]oxazepino[2,3-g]isoquinolin-4-(5H)-one (6)
[0353] At room temperature, (S)-3-(2-benzyl-3-chloro-7-oxo-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)-5-methyl-8-(2,2,2-trifluoroacetyl)-2,3,7,8,9,10-hexahydro-[1,4]oxazepino[2,3-g]isoquinolin-4-(5H)-one (50.0 mg, 0.0850 mmol) was dissolved in MeOH / H2O (2 ml / 0.5 ml), and potassium carbonate (24.0 mg, 0.171 mmol) was added to the reaction solution. Stir overnight at room temperature. Dilute with water, extract with EA (10 mL x 2), dry over anhydrous sodium sulfate, filter, and concentrate under reduced pressure. The residue was separated and purified by high-pressure preparative liquid phase separation (chromatographic column model: Daisogei 30mm*250mm, C18, 10um 100A, mobile phase: acetonitrile / water, gradient: 10%-30%, 30min) to obtain 5 mg of the title compound as an off-white solid, with a yield of 11.9%.
[0354] LC-MS: m / z 492.17 [M+H] + .
[0355] 1 H NMR (400MHz, DMSO-d6) δ7.36-7.29 (m, 3H), 7.20-7.17 (m, 3H), 6.95 (s, 1H), 5.57-5.52 (m, 1H), 5.42 (s, 2H), 4.73-4.7 9(m, 1H), 4.28-4.24(m, 1H), 4.09-4.00(m, 1H), 3.94-3.89(m, 2H), 3.25(s, 3H), 3.10-2.96(m, 3H), 2.80-2.71(m, 5H).
[0356] Example 7: Preparation of (S)-3-(2-benzyl-3-chloro-7-oxo-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)-5,8-dimethyl-2,3,7,8,9,1-hexahydro-[1,4]oxazepino[2,3-g]isoquinolin-4(5H)-one (7)
[0357]
[0358] Step 1: Preparation of (S)-3-(2-benzyl-3-chloro-7-oxo-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)-5,8-dimethyl-2,3,7,8,9,1-hexahydro-[1,4]oxazepino[2,3-g]isoquinolin-4(5H)-one (7)
[0359] At room temperature, (S)-3-(2-benzyl-3-chloro-7-oxo-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)-5-methyl-2,3,7,8,9,1-hexahydro-[1,4]oxazepino[2,3-g]isoquinolin-4(5H)-one (50.0 mg, 0.102 mmol) was dissolved in acetonitrile (3 mL). Formaldehyde (38% in water) (102 mg, 1.02 mmol) and acetic acid (0.3 ml) were added to the reaction solution. The mixture was stirred for 30 minutes, and NaBH3CN (64.0 mg, 1.016 mmol) was added. The mixture was stirred for 2 hours. Saturated NaHCO3 solution was added to the reaction solution, and the mixture was extracted with EA (10 mL x 2) and dried over anhydrous Na2SO4. The mixture was filtered and the filtrate was concentrated under reduced pressure. The residue was separated and purified by high pressure preparative liquid phase separation (chromatographic column model: Daisogei 30mm*250mm, C18, 10um 100A, mobile phase: acetonitrile / water, gradient: 10%-30%, 30min) to obtain 5.2mg of the title compound as a light yellow solid, with a yield of 12.1%.
[0360] LC-MS: m / z 506.19 [M+H] + .
[0361] 1 H NMR (400MHz, CDCl3) δ7.32-7.28(m, 4H), 7.26(s, 1H), 7.01(s, 1H), 6.96(s, 1H), 5.91-5.88(m, 1H), 5.42(s, 2H), 4.66-4.61(m, 1H), 4.42-4.38(m, 1H), 4.30-4.25(m, 1H), 4.02-3.97(m, 2H), 3.58-3.53(m, 2H), 3.37(s, 3H), 3.12-3.05(m, 4H), 2.89(s, 3H).
[0362] Example 8: Preparation of (S)-3-(2-benzyl-3-chloro-7-oxo-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)-5-methyl-8-(methylsulfonyl)-2,3,7,8,9,10-hexahydro-[1,4]oxazepino[2,3-g]isoquinolin-4(5H)-one (12)
[0363]
[0364] Step 1: Preparation of (S)-3-(2-benzyl-3-chloro-7-oxo-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)-5-methyl-8-(methylsulfonyl)-2,3,7,8,9,10-hexahydro-[1,4]oxazepino[2,3-g]isoquinolin-4(5H)-one (8)
[0365] (S)-3-(2-benzyl-3-chloro-7-oxo-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)-5-methyl-2,3,7,8,9,10-hexahydro-[1,4]oxazepino[2,3-g]isoquinolin-4(5H)-one (55.0 mg, 0.0915 mmol) was dissolved in DCM (2 ml) at room temperature, and DIEA (17.3 mg, 0.134 mmol) was added to the reaction solution. Methanesulfonyl chloride (15.3 mg, 0.134 mmol) was added at 0°C, and stirring was continued for 1 hour. Saturated sodium bicarbonate solution was added to the reaction solution, extracted with DCM (15 mL x 3), washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was separated and purified by high-pressure preparative liquid phase separation (chromatographic column model: Daisogei 30 mm*250 mm, C18, 10 um 100A, mobile phase: acetonitrile / water, gradient: 10%-30%, 30 min) to obtain 7.50 mg of the title compound as an off-white solid, with a yield of 11.1%.
[0366] LC-MS: m / z 570.15 [M+H] + .
[0367] 1 HNMR (400MHz, DMSO-d6) δ7.37-7.28(m, 4H), 7.20-7.18(m, 2H), 7.06(br, 1H), 5.58-5.53(m, 1H), 5.43(br, 2H), 4.81(t, 1H), 4.40(br, 2H), 4.29(t, 1H), 4.05-3.99(m, 1H), 3.65-3.59(m, 1H), 3.46-3.42(m, 2H), 3.27(br, 3H) ), 2.96 (br, 3H), 2.93-2.90 (m, 2H), 2.81-2.77 (m, 1H), 2.71-2.66 (m, 1H).
[0368] Example 9: Preparation of (S)-3-(2-benzyl-3-chloro-7-oxo-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)-N,N,5-trimethyl-4-oxo-2,3,4,5,9,10-hexahydro-[1,4]oxazepino[2,3-g]isoquinoline-8(7H)-sulfonamide (9)
[0369]
[0370] The title compound 9 was prepared in the same manner as in Example 8, except that dimethylsulfamoyl chloride was used instead of methanesulfonyl chloride.
[0371] LC-MS: m / z 599.18 [M+H] + .
[0372] 1 H NMR (400MHz, DMSO-d6) δ7.37-7.30 (m, 4H), 7.20-7.18 (m, 2H), 7.06 (s, 1H), 5.58-5.52 (m, 1H), 5.43 (s, 2H), 4.80 (t, 1H), 4.41 (br, 2 H), 4.29 (t, 1H), 4.04-3.99 (m, 1H), 3.64-3.61 (m, 1H), 3.49 (t, 2H), 3.27 (s, 3H), 2.93-2.90 (m, 2H), 2.79 (s, 6H), 2.72-2.68 (m, 2H).
[0373] Example 10: Preparation of (S)-3-(2-benzyl-3-chloro-7-oxo-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)-5-methyl-4-oxo-2,3,4,5,9,10-hexahydro-[1,4]oxazepino[2,3-g]isoquinoline-8(7H)-carbonitrile (10)
[0374]
[0375] The title compound 10 was prepared in the same manner as in Example 8, except that cyanogen bromide was used instead of methanesulfonyl chloride.
[0376] LC-MS: m / z 517.18 [M+H] + .
[0377] 1H NMR (400MHz, DMSO-d6) δ7.32-7.23 (m, 5H), 6.96 (s, 1H), 6.91 (s, 1H), 5.92-5.86 (m, 1H), 5.39 (s, 2H), 4.80 (t, 1 H), 4.33-4.23(m, 3H), 4.26-4.22(m, 1H), 3.57-3.48(m, 3H), 3.35(s, 3H), 3.05-2.95(m, 3H), 2.69-2.64(m, 1H).
[0378] Example 11: Preparation of (S)-3-(2-benzyl-3-chloro-7-oxo-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)-8-(cyclopropanecarbonyl)-5-methyl-2,3,7,8,9,10-hexahydro-[1,4]oxazepino[2,3-g]isoquinolin-4(5H)-one (11)
[0379]
[0380] The title compound 11 was prepared in the same manner as in Example 8, except that cyclopropanecarbonyl chloride was used instead of methanesulfonyl chloride.
[0381] LC-MS: m / z 560.00 [M+H] + .
[0382] 1 H NMR (400MHz, CDCl3) δ7.31-7.29 (m, 5H), 6.99-6.96 (m, 2H), 5.90 (t, 1H), 5.39 (br, 2H ), 4.92-4.87(m, 1H), 4.62-4.54(m, 1H), 4.36(t, 1H), 4.28-4.22(m, 1H), 3.84(br, 1H ), 3.57-3.51(m, 1H), 3.35(br, 3H), 3.08-3.01(m, 1H), 2.94-2.83(m, 2H), 2.68-2.61 (m, 1H), 1.86-1.79 (m, 1H), 1.74-1.61 (m, 1H), 1.45-1.54 (m, 1H), 0.92-0.83 (m, 4H).
[0383] Example 12: Preparation of (8S)-8-(2-benzyl-3-chloro-7-oxo-2,4,5,7-tetrahydro-6H-pyrazolo[3,4c]pyridin-6-yl)-10-methyl-9-oxo-2,3,7,8,9,10-hexahydro-[1,4]dioxino[2′,3′:4,5]benzo[1,2-b][1,4]oxazepine-2-carbonitrile (12)
[0384]
[0385]
[0386] Step 1: Preparation of 4,5-dimethoxy-2-nitrophenol (12a)
[0387] At room temperature, 4,5-dimethoxy-2-nitrobenzaldehyde (5.00 g, 23.7 mmol) was dissolved in 100 mL DCM. At 0°C, m-chloroperbenzoic acid (m-CPBA) (10.9 g, 63.4 mmol) was added. Under nitrogen atmosphere, TFA (1.76 mL) was added at 0°C. The mixture was warmed to room temperature and stirred overnight. At 0°C, saturated sodium thiosulfate solution was added to quench the mixture, filtered, and the filter cake was washed with DCM. The organic phase was washed with saturated sodium bicarbonate solution (100 mL x 1), saturated brine (100 mL x 1), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain a crude product.
[0388] The crude product was dissolved in 70 mL of methanol, 2 mol / L NaOH solution (30 mL) was added, and the mixture was stirred at room temperature for 1 hour. The pH was adjusted to 3-4 with 1 mol / L hydrochloric acid, and the mixture was filtered, and the filter cake was washed with methanol. The filter cake was collected and dried to obtain 3.25 g of the title compound as a yellow solid, with a yield of 69.0%.
[0389] LC-MS: m / z 200.05 [M+H] + .
[0390] Step 2: Preparation of O-(4,5-dimethoxy-2-nitrophenyl)-N-trityl-L-serine methyl ester (12b)
[0391] At room temperature, 4,5-dimethoxy-2-nitrophenol (3.25 g, 12.3 mmol), methyltrityl-L-serine (6.64 g, 18.4 mmol) and triphenylphosphine (6.45 g, 24.5 mmol) were dissolved in 150 mL of THF. Under nitrogen atmosphere, diisopropyl azodicarboxylate (DIAD) (4.95 g, 24.5 mmol) was added at 0°C, and the mixture was heated to room temperature and stirred overnight. 100 mL of water was added to quench, and the mixture was extracted with EA (100 mL x 3), washed with saturated brine (150 mL x 1), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was separated and purified by silica gel column chromatography (mobile phase: PE / EA = 100:1-2:1) to obtain 13.2 g of the title compound as a yellow oil (crude product).
[0392] Step 3: Preparation of O-(4,5-dimethoxy-2-nitrophenyl)-L-serine methyl ester (12c)
[0393] Dissolve O-(4,5-dimethoxy-2-nitrophenyl)-N-trityl-L-serine methyl ester (13.2 g, 21.7 mmol) in 100 ml of DCM, add 4 mol / L hydrochloric acid / dioxane solution (20 mL), stir at room temperature overnight, concentrate under reduced pressure, beat three times (EA / PE=3:1), filter, and dry the filter cake to obtain 3.05 g of the title compound as a light yellow solid, with a yield of 46.8%.
[0394] LC-MS: m / z 301.10 [M+H] + .
[0395] Step 4: Preparation of N-(tert-butoxycarbonyl)-O-(4,5-dimethoxy-2-nitrophenyl) L-serine methyl ester (12d)
[0396] Dissolve O-(4,5-dimethoxy-2-nitrophenyl)-L-serine methyl ester (3.05 g, 10.2 mmol) in 50 mL DCM, add DIEA (3.93 g, 30.5 mmol), and stir at room temperature for 20 minutes. Add Boc2O (3.32 g, 15.2 mmol) in batches at 0°C, and stir at room temperature overnight. Add 100 mL of water, extract with DCM (50 mL x 2), wash with saturated brine (100 mL x 1), dry over anhydrous sodium sulfate, filter, and concentrate the filtrate under reduced pressure to obtain 5.01 g (crude) of the title compound as a yellow oil.
[0397] LC-MS: m / z 401.15 [M+H] + .
[0398] Step 5: Preparation of O-(2-amino-4,5-dimethoxyphenyl)-N-(tert-butyloxycarbonyl)-L-serine methyl ester (12e)
[0399] Dissolve N-(tert-butoxycarbonyl)-O-(4,5-dimethoxy-2-nitrophenyl)-L-serine methyl ester (5.01 g, 12.5 mmol) in 50 ml MeOH, add palladium carbon (10 wt%, 2.50 g), stir overnight at room temperature under hydrogen atmosphere. Filter, wash the filter cake with methanol (10 mL x 3), and concentrate the filtrate under reduced pressure to obtain 4.75 g (crude) of the title compound as a black oil.
[0400] LC-MS: m / z 371.17 [M+H] + .
[0401] Step 6: Preparation of tert-butyl (S)-(7,8-dimethoxy-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]oxazepin-3-yl)carbamate (12f)
[0402] Dissolve O-(2-amino-4,5-dimethoxyphenyl)-N-(tert-butyloxycarbonyl)-L-serine methyl ester (4.75 g, 12.5 mmol) in CHCl3 (80 ml). Add trimethylaluminum solution (2.7 mL, 2 mol / L) to the reaction solution at 0°C under nitrogen atmosphere. Stir at 50°C for 3 hours. Add methanol to quench, concentrate under reduced pressure, slurry the residue with DCM / MeOH=5:1 (10 mL x 5), filter, collect the filtrate, and concentrate under reduced pressure to obtain 2.65 g of the title compound as a black oil, yield: 62.8%.
[0403] LC-MS: m / z 339.15 [M+H] + .
[0404] Step 7: ( Preparation of tert-butyl S)-(7,8-dimethoxy-5-methyl-4-oxo-2,3,4,5-tetrahydro-benzo[b][1,4]oxazepin-3-yl)carbamate (12 g)
[0405] Dissolve (S)-(7,8-dimethoxy-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]oxazepin-3-yl)carbamic acid tert-butyl ester (2.65 g, 7.84 mmol) in 35 mL DMF, add cesium carbonate (3.83 g, 11.7 mmol), and stir at room temperature for 30 minutes. Add iodomethane (1.11 g, 7.82 mmol) at 0°C and stir at room temperature for 2 hours. Add 50 mL of water, extract with EA (30 mL x 3), wash with saturated brine (30 mL x 2), dry over anhydrous sodium sulfate, filter, and concentrate the filtrate under reduced pressure. The residue is separated and purified by silica gel column chromatography (mobile phase: PE / EA = 100:1-3:1) to obtain 650 mg of the title compound as a yellow oil, yield: 23.6%.
[0406] LC-MS: m / z 353.16 [M+H] + .
[0407] Step 8: Preparation of (S)-3-amino-7,8-dimethoxy-5-methyl-2,3-dihydro-benzo[b][1,4]oxazepin-4(5H)-one (12h)
[0408] Will (S)-(7,8-dimethoxy-5-methyl-4-oxo-2,3,4,5-tetrahydro-benzo[b][1,4]oxazepin-3-yl)carbamic acid tert-butyl (650 mg, 1.85 mmol) was dissolved in DCM (10 ml), 4 mol / L hydrochloric acid / dioxane solution (3 mL) was added to the reaction solution, and stirred at room temperature overnight. 10 mL of saturated sodium bicarbonate solution was added, and DCM was extracted (10 mL x 3), washed with saturated brine (15 mL x 1), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain 380 mg of the yellow semi-solid title compound, with a yield of 81.7%.
[0409] LC-MS: m / z 253.27 [M+H] + .
[0410] Step 9: Preparation of (S)-1-benzyl-5-chloro-4-(2-((7,8-dimethoxy-5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]oxazepin-3-yl)amino)ethyl)-1H-pyrazole-3-carboxylic acid ethyl ester (12i)
[0411] (S)-3-amino-7,8-dimethoxy-5-methyl-2,3-dihydrobenzo[b][1,4]oxazepine-4(5H)-one (360 mg, 1.43 mmol), 1-benzyl-5-chloro-4-(2-oxoethyl)-1H-pyrazole-3-carboxylic acid ethyl ester (11) (612 mg, 2.00 mmol) were dissolved in 10 mL of methanol, 1 mL of glacial acetic acid and 2-methylpyridine borane (214 mg, 2.00 mmol) were added, and stirred at room temperature for 2 hours. 20 mL of saturated sodium bicarbonate solution was added, extracted with DCM (10 mL x 3), washed with saturated brine (20 mL x 1), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was separated and purified by silica gel column chromatography (mobile phase: PE / EA=100:1-2:3) to obtain 400 mg of the title compound as a reddish brown solid, yield: 51.6%.
[0412] LC-MS: m / z 543.19 [M+H] + .
[0413] Step 10: Preparation of (S)-3-(2-benzyl-3-chloro-7-oxo-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)-7,8-dimethoxy-5-methyl-2,3-dihydro-benzo[b][1,4]oxazepin-4(5H)-one (12j)
[0414] Dissolve (S)-1-benzyl-5-chloro-4-(2-((7,8-dimethoxy-5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]oxazepin-3-yl)amino)ethyl)-1H-pyrazole-3-carboxylic acid ethyl ester (350 mg, 0.644 mmol) in 5 ml of toluene. Add Al(CH3)3 toluene solution (0.97 mL, 2 mol / L) at 0°C under nitrogen atmosphere, and stir at 90°C for 3 hours. Add 10 mL of water to quench, extract with EA (10 mL x 3), wash with saturated brine (10 mL x 1), dry over anhydrous sodium sulfate, filter, and concentrate under reduced pressure. The residue is separated and purified by silica gel column chromatography (mobile phase: PE / EA = 100:1-1:1) to obtain 330 mg of the title compound as a light red solid (crude product).
[0415] LC-MS: m / z 496.29 [M+H] + .
[0416] Step 11: Preparation of (S)-3-(2-benzyl-3-chloro-7-oxo-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)-7,8-dihydroxy-5-methyl-2,3-dihydro-benzo[b][1,4]oxazepin-4(5H)-one (12k)
[0417] At room temperature, (S)-3-(2-benzyl-3-chloro-7-oxo-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)-7,8-dimethoxy-5-methyl-2,3-dihydro-benzo[b][1,4]oxazepin-4(5H)-one (250 mg, 0.503 mmol) was dissolved in 6 mL of dichloromethane, and a dichloromethane solution of boron tribromide (1 M, 3 mL) was added at 0°C, and stirred at room temperature for 2 hours. Methanol was added dropwise at 0°C to quench, and the mixture was extracted with DCM (10 mL x 3), washed with saturated brine (20 mL x 1), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain 270 mg of the title compound as a reddish brown solid (crude product).
[0418] LC-MS: m / z 469.12 [M+H] + .
[0419] Step 12: Preparation of (8S)-8-(2-benzyl-3-chloro-7-oxo-2,4,5,7-tetrahydro-6H-pyrazolo[3,4c]pyridin-6-yl)-10-methyl-9-oxo-2,3,7,8,9,10-hexahydro-[1,4]dioxino[2′,3′:4,5]benzo[1,2-b][1,4]oxazepine-2-carbonitrile (12)
[0420] (S)-3-(2-Benzyl-3-chloro-7-oxo-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)-7,8-dihydroxy-5-methyl-2,3-dihydrobenzo[b][1,4]oxazepin-4(5H)-one (100 mg, 0.214 mmol) was dissolved in 3 ml of acetonitrile, potassium carbonate (88.5 mg, 0.641 mg) and 2,3-dibromopropanenitrile (59.2 mg, 0.278 mmol) were added, and the mixture was stirred at 75°C overnight. The mixture was quenched with 10 mL of water, extracted with EA (10 mL x 3), washed with saturated brine (10 mL x 1), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by high pressure preparative liquid separation (chromatographic column model: Daisogei 30 mm × 250 mm, C18, 10 um 100A, mobile phase: acetonitrile / water (0.05% formic acid), gradient: 30%-70%) to give 10.0 mg of the title compound as a light yellow solid, yield: 9.01%.
[0421] LC-MS: m / z 520.13 [M+H] + .
[0422] 1 H NMR (400MHz, CDCl3) δ: 7.38-7.19 (m, 6H), 7.00-6.94 (m, 1H), 5.88-5.81 (m, 1H), 5.62-5.52 (m, 1H), 5.45 (br, 2H), 4.84-4.74 (m, 1H), 4.72-4.62 (m, 1H), 4.55-4.35 (m, 2H), 4.09-3.98 (m, 1H), 3.71-3.56 (m, 1H), 3.32-3.23 (m, 4H), 2.87-2.77 (m, 1H), 2.75-2.65 (m, H).
[0423] Example 13: Preparation of (8S)-8-(2-benzyl-3-chloro-7-oxo-2,4,5,7-tetrahydro-6-pyrazolo[3,4c]pyridin-6-yl)-10-methyl-9-oxo-2,3,7,8,9,10-hexahydro-[1,4]dioxino[2′,3′:4,5]benzo[1,2-b][1,4]oxazepine-2-carboxamide (13)
[0424]
[0425] (8S)-8-(2-Benzyl-3-chloro-7-oxo-2,4,5,7-tetrahydro-6H-pyrazolo[3,4c]pyridin-6-yl)-10-methyl-9-oxo-2,3,7,8,9,10-hexahydro-[1,4]dioxino[2′,3′:4,5]benzo[1,2-b][1,4]oxazepine-2-carbonitrile (120 mg, 0.231 mmol) was dissolved in 3 ml of DMSO, potassium carbonate (3.18 mg, 0.0230 mg) and hydrogen peroxide (1 mL, 30%) were added at 0°C, and the mixture was stirred at room temperature for 1 hour. The mixture was quenched by adding 15 mL of saturated sodium sulfite solution, extracted with EA (10 mL x 3), washed with saturated brine (10 mL x 1), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was separated by high pressure preparative liquid chromatography (chromatographic column model: Daisogei 30 mm*250 mm, C18, 10 um 100A, mobile phase: acetonitrile / water (0.05% formic acid), gradient: 30%-70%) to give 7.0 mg of the title compound as a light yellow solid. The yield was 5.64%.
[0426] LC-MS: m / z 538.14 [M+H] + .
[0427] 1 H NMR (400MHz, CDCl3) δ: 7.62-7.49 (m, 2H), 7.42-7.25 (m, 3H), 7.24-7.16 (m, 2H), 7.12 (s, 1H), 6.85 (s, 1H), 5.62-5.51 (m, 1H), 5.43 (s, 2H), 4.8 9-4.82(m, 1H), 4.79-4.69(m, 1H), 4.40-4.24(m, 3H), 4.08-3.97(m, 1H) , 3.68-3.56 (m, 1H), 3.23 (s, 3H), 2.90-2.75 (m, 1H), 2.72-2.62 (m, 1H).
[0428] Example 14: Preparation of (S)-8-(2-benzyl-3-chloro-7-oxo-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)-4-isopropyl-10-methyl-4,7,8,10-tetrahydro-2H-[1,4]oxazino[2′,3′:4,5]benzo[1,2-b][1,4]oxazepine-3,9-dione (14)
[0429]
[0430] Step 1: Preparation of 6-methoxy-7-nitro-2H-benzo[b][1,4]oxazin-3(4H)-one (14a)
[0431] At room temperature, 6-methoxy-2H-benzo[b][1,4]oxazin-3-(4H)-one was dissolved in 9 ml of glacial acetic acid. At 0°C, concentrated nitric acid (3 mL) was added and stirred at 0°C for 1 hour. The reaction solution was poured into ice water, filtered, and the filter cake was washed with water (5 mL x 3) and dried to obtain 2.99 g of the title compound as a yellow solid, with a yield of 97.7%.
[0432] LC-MS: m / z 225.04 [M+H] + .
[0433] Step 2: Preparation of 4-isopropyl-6-methoxy-7-nitro-2H-benzo[b][1,4]oxazin-3-(4H)-one (14b)
[0434] At room temperature, 6-methoxy-7-nitro-2H-benzo[b][1,4]oxazin-3-(4H)-one (2.40 g, 10.7 mmol) was dissolved in 35 mL of DMF. At 0°C, NaH (1.28 g, 32.0 mmol) was added. The mixture was stirred at room temperature for 30 minutes. At 0°C, isopropyl iodide (5.46 g, 32.1 mmol) was added. The mixture was sealed and stirred at 80°C for 2 hours. 30 mL of saturated ammonium chloride solution was added to quench the mixture, and the mixture was extracted with EA (30 mL x 3), washed with saturated brine (30 mL x 1), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was separated and purified by silica gel column chromatography (mobile phase: PE / EA = 100:1-3:1) to obtain 710 mg of the title compound as a light reddish brown solid, with a yield of 24.9%.
[0435] LC-MS: m / z 267.09 [M+H] + .
[0436] Step 3: Preparation of 6-hydroxy-4-isopropyl-7-nitro-2H-benzo[b][1,4]oxazin-3-(4H)-one (14c)
[0437] At room temperature, 4-isopropyl-6-methoxy-7-nitro-2H-benzo[b][1,4]oxazin-3-(4H)-one (300 mg, 1.13 mmol) was dissolved in 5 ml of dichloromethane. Under nitrogen atmosphere, 1 mol / L BBr3 solution (2.26 mL) was added at 0°C. The mixture was stirred at room temperature for 1 hour. Methanol was added at 0°C to quench the mixture, 10 mL of water was added, and the mixture was extracted with DCM (10 mL x 3), washed with saturated brine (20 mL x 1), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain 310 mg of the title compound as a light yellow solid (crude product).
[0438] LC-MS: m / z 253.1[M+H] + .
[0439] The other steps were the same as the preparation method of Example 1, except that 6-hydroxy-4-isopropyl-7-nitro-2H-benzo[b][1,4]oxazine-3-(4H)-one (14c) was used instead of 3-nitro-5,6,7,8-tetrahydronaphthalen-2-ol (1a) in step 2 to obtain the title compound 14.
[0440] LC-MS: m / z 550.18 [M+H] + .
[0441] 1 H NMR (400MHz, CDCl3) δ7.37-7.29 (m, 3H), 7.28-7.24 (m, 2H), 6.97 (s, 1H), 6.89 (s, 1H), 6.02-5.91 (m, 1H), 5.43 (s, 2H), 4.75-4.59 (m, 2H), 4.58 -4.53(m, 2H), 4.47-4.39(m, 1H), 4.32-4.23(m, 1H), 3.62-3.52(m, 1H) , 3.35 (s, 3H), 3.14-3.04 (m, 1H), 2.74-2.64 (m, 1H), 1.70-1.58 (m, 6H).
[0442] Example 15: Preparation of (S)-8-(cyclopropanecarbonyl)-3-(2-(2-fluorobenzyl)-7-oxo-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)-5-methyl-2,3,7,8,9,10-hexahydro-[1,4]oxazepino[2,3-g]isoquinolin-4(5H)one (15)
[0443]
[0444] Step 1: Preparation of ethyl 1-(2-fluorobenzyl)-1H-pyrazole-3-carboxylate (15a)
[0445] Dissolve 1H-pyrazole-3-carboxylic acid ethyl ester (2.00 g, 14.3 mmol) in 25 mL of tetrahydrofuran, add NaH (686 mg, 17.1 mmol) at 0°C, stir for 20 minutes, add 1-(bromomethyl)-2-fluorobenzene (2.97 g, 15.7 mmol), and stir overnight at room temperature. Quench with saturated ammonium chloride solution, add 30 mL of water and 15 mL of ethyl acetate, wash the organic layer with 20 mL of saturated brine, dry over anhydrous sodium sulfate, filter, and concentrate the filtrate under reduced pressure. The residue is separated and purified by silica gel column chromatography (mobile phase: PE / EA=100:1-15:1) to obtain 2.78 g of the title compound as a light yellow oil, with a yield of 78.5%.
[0446] LC-MS: m / z 249.1[M+H] + .
[0447] Step 2: Preparation of ethyl 4-bromo-1-(2-fluorobenzyl)-1H-pyrazole-3-carboxylate (15b)
[0448] At room temperature, ethyl 1-(2-fluorobenzyl)-1H-pyrazole-3-carboxylate (2.68 g, 10.8 mmol) was dissolved in 35 mL of DMF, and NBS (2.12 g, 11.9 mmol) was added dropwise, and stirred at room temperature overnight. The reaction solution was slowly poured into water, and 30 mL of ethyl acetate was added. The organic phase was washed with 20 mL of saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain 4.25 g (crude) of the title compound as a reddish brown solid.
[0449] LC-MS: m / z 327.0 [M+H] + .
[0450] Step 3: Preparation of (E)-ethyl 4-(2-ethoxyvinyl)-1-(2-fluorobenzyl)-1H-pyrazole-3-carboxylate (15c)
[0451] At room temperature, ethyl 4-bromo-1-(2-fluorobenzyl)-1H-pyrazole-3-carboxylate (4.25 g, 10.8 mmol) and (E)-2-(2-ethoxyvinyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane were dissolved in 56 mL of DME and 7 mL of water, and cesium carbonate (8.80 g, 27.0 mmol) and Pd(dppf)2Cl2 (789 mg, 1.08 mmol) were added, and the mixture was stirred at 90°C overnight. 60 mL of water and 40 mL of ethyl acetate were added to the reaction solution, and the organic phase was washed with 50 mL of saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was separated and purified by silica gel column chromatography (mobile phase: PE / EA=100:1-3:1) to obtain 3.08 g of the title compound as a yellow oil, with a yield of 74.6%.
[0452] LC-MS: m / z 319.1[M+H] + .
[0453] Step 4: Preparation of ethyl 1-(2-fluorobenzyl)-4-(2-oxoethyl)-1H-pyrazole-3-carboxylate (15d)
[0454] At room temperature, (E)-4-(2-ethoxyvinyl)-1-(2-fluorobenzyl)-1H-pyrazole-3-carboxylic acid ethyl ester (500 mg, 1.57 mmol) was dissolved in 10 mL of THF, and 5 mL of 6N hydrochloric acid was added. The mixture was stirred at room temperature for 2.5 hours. The reaction solution was poured into 20 mL of saturated sodium bicarbonate solution, and 30 mL of ethyl acetate was added. The organic phase was washed with 20 mL of saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain 270 mg of the title compound as a colorless oil, with a yield of 59.2%.
[0455] LC-MS: m / z 291.1 [M+H] + .
[0456] Step 5: Preparation of (S)-1-(2-fluorobenzyl)-4-(2-((5-methyl-4-oxo-8-(2,2,2-trifluoroacetyl)-2,3,4,5,7,8,9,10-octahydro-[1,4]oxazepino[2,3-g]isoquinolin-3-yl)amino)ethyl)-1H-pyrazole-3-carboxylic acid methyl ester (15e)
[0457] At room temperature, (S)-3-amino-5-methyl-8-(2,2,2-trifluoroacetyl)-2,3,7,8,9,10-hexahydro-[1,4]oxazepino[2,3-g]isoquinolin-4(5H)-one (5j) (140 mg, 0.271 mmol) and ethyl 1-(2-fluorobenzyl)-4-(2-oxoethyl)-1H-pyrazole-3-carboxylate (94.3 mg, 0.325 mmol) were dissolved in 3 mL of methanol. AcOH (0.3 ml) and 2-methylpyridine borane (40.6 mg, 0.379 mmol) were added to the reaction solution, and the mixture was stirred at room temperature for 2 hours. Saturated NaHCO3 solution was added, extracted with EA (15 mL x 3), washed with saturated brine (20 mL x 1), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain 80.0 mg of the title compound as a light yellow solid. The yield was 32.5%.
[0458] LC-MS: m / z 604.21 [M+H] + .
[0459] Step 6: Preparation of (S)-3-(2-(2-fluorobenzyl)-7-oxo-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)-5-methyl-8-(2,2,2-trifluoroacetyl)-2,3,7,8,9,10-hexahydro-[1,4]oxazepino[2,3-g]isoquinolin-4(5H)-one (15f)
[0460] Compound 15e (80.0 mg, 0.130 mmol) was dissolved in 4 ml of chloroform at room temperature. Al(CH3)3 (2M) (0.19 ml, 0.389 mmol) was added to the reaction solution at 0°C under nitrogen atmosphere. The mixture was stirred at 50°C for 2 hours. The mixture was quenched with water, filtered through diatomaceous earth, and the filter cake was washed with EA. The filtrate was diluted with water, extracted with EA (20 mL x 3), washed with saturated brine (20 mL x 1), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was separated and purified by thin layer chromatography (PE / EA = 4:1) to obtain 100.0 mg (crude) of the title compound as a pale yellow solid.
[0461] LC-MS: m / z 572.18 [M+H] + .
[0462] Step 7: Preparation of (S)-3-(2-(2-fluorobenzyl)-7-oxo-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)-5-methyl-2,3,7,8,9,10-hexahydro-[1,4]oxazepino[2,3-g]isoquinolin-4(5H)-one (15 g)
[0463] Compound 15f (100 mg, 0.175 mmol) was dissolved in MeOH / H2O (3 ml / 0.7 ml) at room temperature, potassium carbonate (36.2 mg, 0.262 mmol) was added to the reaction solution, and stirred at room temperature overnight. The mixture was diluted with water, extracted with DCM (20 mL x 3), washed with saturated brine (20 mL x 1), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain 90.0 mg (crude) of the title compound as a light yellow solid.
[0464] LC-MS: m / z 476.20 [M+H] + .
[0465] Step 8: Preparation of (S)-8-(cyclopropanecarbonyl)-3-(2-(2-fluorobenzyl)-7-oxo-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)-5-methyl-2,3,7,8,9,10-hexahydro-[1,4]oxazepino[2,3-g]isoquinolin-4(5H)one (15)
[0466] At room temperature, compound 15g (80.0mg, 0.168mmol) was dissolved in DCM (2ml), and DIEA (43.4mg, 0.336mmol) was added to the reaction solution. At 0°C, cyclopropanecarbonyl chloride (35.3mg, 0.336mmol) was added. Then, the mixture was stirred at room temperature overnight. 10ml of saturated sodium bicarbonate solution was added, and DCM was extracted (15mL x 3), washed with saturated brine (20mL x 1), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was separated by high pressure preparative liquid chromatography (chromatographic column model: Daisogei 30mm*250mm, C18, 10um 100A, mobile phase: acetonitrile / water, gradient: 10%-30%, 30min), and 10.0mg of the title compound was obtained as an off-white solid with a yield of 10.9%.
[0467] LC-MS: m / z 544.23 [M+H] + .
[0468] 1 HNMR (400MHz, DMSO-d6) δ: 7.74 (s, 1H), 7.43-7.32 (m, 2H), 7.26-7.14 (m, 3H), 7.07 (s, 1H), 5.62-5.52 (m, 1H), 5.42 (s, 2H), 4.93 (s, 1H) , 4.78 (t, 1H), 4.64 (d, 1H), 4.26 (t, 1H), 4.08-3.86 (m, 3H), 3.78-3.49 (m, 3H), 3.47-3.29 (m, 5H), 1.31-1.19 (m, 3H), 0.78-0.75 (m, 2H).
[0469] Example 16: Preparation of (S)-8-(2-benzyl-3-chloro-7-oxo-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)-10-methyl-4-(methyl-d3)-4,7,8,10-tetrahydro-2H-[1,4]oxazino[2′,3′:4,5]benzo[1,2-b][1,4]oxazepine-3,9-dione (16)
[0470]
[0471] Step 1: Preparation of 6-methoxy-4-(methyl-d3)-2H-benzo[b][1,4]oxazin-3(4H)-one (16a)
[0472] At room temperature, 6-methoxy-2H-benzo[b][1,4]oxazine-3(4H)-one (1.91 g, 10.7 mmol) was dissolved in 30 mL DMF. At 0°C, NaH (1.02 g, 25.5 mmol) was added. The mixture was stirred at room temperature for 30 minutes. At 0°C, deuterated iodomethane (2.47 g, 17.0 mmol) was added. The mixture was sealed and stirred at 80°C for 2 hours. 30 mL of saturated ammonium chloride solution was added to quench the mixture, and the mixture was extracted with EA (30 mL x 3), washed with saturated brine (30 mL x 1), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was separated and purified by silica gel column chromatography (mobile phase: PE / EA = 100:1-3:1) to obtain 1.33 g of the title compound as an off-white solid, with a yield of 63.6%.
[0473] LC-MS: m / z 197.09 [M+H] + .
[0474] Step 2: Preparation of 6-methoxy-4-(methyl-d3)-7-nitro-2H-benzo[b][1,4]oxazin-3(4H)-one (16b)
[0475] At room temperature, dissolve 6-methoxy-4-(methyl-d3)-2H-benzo[b][1,4]oxazin-3(4H)-one in 12 ml of glacial acetic acid. Add concentrated nitric acid (3 mL) at 0°C. Stir at 0°C for 1 hour. Pour the reaction solution into ice water, filter, wash the filter cake with water (5 mL x 3), and dry to obtain 1.58 g (crude) of the title compound as a yellow solid.
[0476] LC-MS: m / z 242.08 [M+H] + .
[0477] Step 3: Preparation of 6-hydroxy-4-(methyl-d3)-7-nitro-2H-benzo[b][1,4]oxazin-3(4H)-one (16c)
[0478] At room temperature, 6-methoxy-4-(methyl-d3)-7-nitro-2H-benzo[b][1,4]oxazin-3(4H)-one (1.35 g, 5.60 mmol) was dissolved in 20 ml of dichloromethane. Under nitrogen atmosphere, 1 mol / L BBr3 solution (11.2 mL) was added at 0°C. Stir at room temperature for 1 hour. Methanol was added to quench at 0°C, 50 mL of water was added, and DCM was extracted (50 mL x 3), washed with saturated brine (100 mL x 1), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain 1.34 g (crude) of the title compound as a yellow solid.
[0479] LC-MS: m / z 228.06 [M+H]+ .
[0480] The title compound 16 was prepared by the same preparation method as in Example 1, except that 6-hydroxy-4-(methyl-d3)-7-nitro-2H-benzo[b][1,4]oxazine-3(4H)-one (16c) was used instead of 3-nitro-5,6,7,8-tetrahydronaphthalen-2-ol (1a) in step 2.
[0481] LC-MS: m / z 525.17 [M+H] + .
[0482] 1 H NMR (400MHz, DMSO-d6) δ: 7.38-7.28 (m, 3H), 7.23-7.16 (m, 3H), 7.09 (s, 1H), 5.63-5.54 (m, 1H), 5.43 (br, 2H), 4.84-4.76 (m, 1H) , 4.74-4.64(m, 2H), 4.38-4.29(m, 1H), 4.08-3.97(m, 1H), 3.68-3.58(m, 1H), 3.26(s, 3H), 2.87-2.75(m, 1H), 2.72-2.64(m, 1H).
[0483] Example 17: Preparation of (S)-3-(2-benzyl-3-chloro-7-oxo-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)-1-methyl-9-(2,2,2-trifluoroacetyl)-3,4,8,9,10,11-hexahydro-[1,4]oxazepino[3,2-f]isoquinolin-2(1H)-one (17)
[0484]
[0485] Step 1: Preparation of 2,2,2-trifluoro-1-(6-methoxy-5-nitro-3,4-dihydroisoquinolin-2-(1H)-yl)ethan-1-one (17a)
[0486] 2,2,2-Trifluoro-1-(6-methoxy-3,4-dihydroisoquinolin-2-(1H-yl)ethan-1-one (5a) (6.50 g, 25.1 mmol) was dissolved in MeCN (90 mL), and NaNO3 (2.14 g, 25.1 mmol) was added. TFAA (8.44 g, 40.2 mmol) was added dropwise to the reaction solution at 0°C under a nitrogen atmosphere, and the reaction solution was warmed to room temperature and stirred overnight. The reaction solution was quenched with water, extracted with EA (120 mL x 2), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was separated and purified by silica gel column chromatography (mobile phase: PE / EA=3:1) to obtain 3 g of the title compound as a light yellow solid in a yield of 39.3%.
[0487] LC-MS: m / z 305.07 [M+H] + .
[0488] The other steps were the same as the preparation method of Example 5, except that 2,2,2-trifluoro-1-(6-methoxy-5-nitro-3,4-dihydroisoquinolin-2-(1H)-yl)ethan-1-one (17a) was used instead of 2,2,2-trifluoro-1-(6-methoxy-7-nitro-3,4-dihydroisoquinolin-2-(1H)-yl)ethan-1-one (5b), to obtain the title compound 17.
[0489] LC-MS: m / z 588.15 [M+H] + .
[0490] 1 HNMR (400MHz, DMSO-d6) δ7.37-7.28(m, 4H), 7.20-7.17(m, 3H), 5.55-5.50(m, 1H), 5.43(br, 2H), 5.04-4.58(m, 3H), 4.2 1 (t, 1H), 4.12-4.06 (m, 2H), 3.65-3.50 (m, 2H), 3.13 (br, 3H), 3.03-2.94 (m, 1H), 2.81-2.75 (m, 2H), 2.71-2.66 (m, 1H).
[0491] Example 18: Preparation of (S)-3-(2-benzyl-3-chloro-7-oxo-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)-1-methyl-3,4,8,9,10,11-hexahydro-[1,4]oxazepino[3,2-f]isoquinolin-2(1H)-one (18)
[0492]
[0493] The preparation method was the same as that of Example 6, except that (S)-3-(2-benzyl-3-chloro-7-oxo-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)-1-methyl-9-(2,2,2-trifluoroacetyl)-3,4,8,9,10,11-hexahydro-[1,4]oxazepino[3,2-f]isoquinolin-2(1H)-one (1 7) Substituting (S)-3-(2-benzyl-3-chloro-7-oxo-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)-5-methyl-8-(2,2,2-trifluoroacetyl)-2,3,7,8,9,10-hexahydro-[1,4]oxazepino[2,3-g]isoquinolin-4-(5H)-one (5) to obtain the title compound 18.
[0494] LC-MS: m / z 492.17 [M+H] + .
[0495] 1 H NMR (400MHz, DMSO-d6) δ8.30 (br, 1H), 7.37-7.28 (m, 3H), 7.19-7.17 (m, 2H), 7.06 (br, 2H), 5.51-5.46 (m, 1H), 5.43 (br, 2H), 4.73-4.68 (m, 1H), 4.19-4.15(m, 1H), 4.11-4.05(m, 1H), 3.95(br, 2H), 3.65-3.58(m, 2H), 3.20-3.16 (m, 1H), 3.11 (br, 3H), 2.84-2.75 (m, 3H), 2.71-2.61 (m, 1H).
[0496] Example 19: Preparation of (S)-3-(2-benzyl-3-chloro-7-oxo-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)-9-(cyclopropylsulfonyl)-1-methyl-3,4,8,9,10,11-hexahydro-[1,4]oxazepino[3,2-f]isoquinolin-2(1H)-one (19)
[0497]
[0498] Step 1: Preparation of (S)-3-(2-benzyl-3-chloro-7-oxo-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)-9-(cyclopropylsulfonyl)-1-methyl-3,4,8,9,10,11-hexahydro-[1,4]oxazino[3,2-f]isoquinolin-2(1H)-one (19).
[0499] (S)-3-(2-benzyl-3-chloro-7-oxo-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)-1-methyl-3,4,8,9,10,11-hexahydro-[1,4]oxazepino[3,2-f]isoquinolin-2(1H)-one (30.0 mg, 0.0610 mmol) was dissolved in DCM (2 ml) at room temperature, and DIEA (15.7 mg, 0.122 mmol) was added to the reaction solution. Cyclopropanesulfonyl chloride (10.3 mg, 0.0729 mmol) was added at 0°C. The mixture was stirred at room temperature overnight. Add 5 ml of water, extract with DCM (5 mL x 3), wash with saturated brine (10 mL x 1), dry over anhydrous sodium sulfate, filter, and concentrate the filtrate under reduced pressure. The residue is separated and purified by high-pressure preparative liquid phase separation (chromatographic column model: Daisogei 30 mm × 250 mm, C18, 10 um 100A, mobile phase: acetonitrile / water, gradient: 10%-30%, 30 min) to obtain 10.0 mg of the title compound as a white solid, with a yield of 27.8%.
[0500] LC-MS: m / z 596.17 [M+H] + .
[0501] 1 H NMR (400MHz, CDCl3) δ7.38-7.28(m, 3H), 7.28-7.17(m, 2H), 7.11-7.00(m, 2H), 5.90-5.80(m, 1H), 5.41(s, 2H), 4.80-4.75(m, 1H), 4.62-4. 51 (m, 1H), 4.49-4.20 (m, 4H), 4.10-4.00 (m, 1H), 3.68-3.45 (m, 2H), 3 .21(s, 3H), 3.19-2.91(m, 4H), 2.88-2.61(m, 3H), 2.41-2.31(m, 1H).
[0502] Example 20: Preparation of (S)-3-(2-benzyl-3-chloro-7-oxo-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)-1-methyl-9-(pyrrolidin-1-ylsulfonyl)-3,4,8,9,10,11-hexahydro-[1,4]oxazepino[3,2-f]isoquinolin-2(1H)-one (20)
[0503]
[0504] Step 1: Preparation of (S)-3-(2-benzyl-3-chloro-7-oxo-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)-1-methyl-9-(pyrrolidin-1-ylsulfonyl)-3,4,8,9,10,11-hexahydro-[1,4]oxazepino[3,2-f]isoquinolin-2(1H)-one (20)
[0505] At room temperature, compound 18 (30.0 mg, 0.0610 mmol) was dissolved in DCM (2 ml), and DIEA (15.7 mg, 0.122 mmol) was added to the reaction solution. Pyrrolidine-1-sulfonyl chloride (124 mg, 0.0729 mmol) was added at 0°C. The mixture was stirred overnight at room temperature. 5 ml of water was added, and the mixture was extracted with DCM (5 mL x 3), washed with saturated brine (10 mL x 1), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by high pressure preparative liquid separation (chromatographic column model: Daisogei 30 mm × 250 mm, C18, 10 um 100A, mobile phase: acetonitrile / water, gradient: 10%-30%, 30 min) to obtain 8.00 mg of the title compound as a white solid, with a yield of 21.0%.
[0506] LC-MS: m / z 625.19 [M+H] + .
[0507] 1 H NMR (400MHz, CDCl3) δ7.38-7.29 (m, 3H), 7.28-7.24 (m, 2H), 7.10-7.02 (m, 2H), 5.92-5.84 (m, 1H), 5.41 (s, 2H), 4.72-4.54 (m, 2H), 4.40-4. 27(m, 3H), 4.04-3.95(m, 1H), 3.62-3.52(m, 1H), 3.45-3.35(m, 4H), 3 .23(s, 3H), 3.19-2.94(m, 3H), 2.82-2.63(m, 2H), 2.01-1.91(m, 4H).
[0508] Example 21: Preparation of (S)-3-(2-benzyl-3-chloro-7-oxo-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)-N,N,1-trimethyl-2-oxo-1,2,3,4,10,11-hexahydro-[1,4]oxazepino[3,2-f]isoquinoline-9(8H)-carboxamide (21)
[0509]
[0510] Step 1: Preparation of (S)-3-(2-benzyl-3-chloro-7-oxo-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)-N,N,1-trimethyl-2-oxo-1,2,3,4,10,11-hexahydro-[1,4]oxazepino[3,2-f]isoquinoline-9(8H)-carboxamide (21)
[0511] At room temperature, compound 18 (30.0 mg, 0.0610 mmol) was dissolved in DCM (2 ml), and DIEA (15.7 mg, 0.122 mmol) was added to the reaction solution. Dimethylcarbamoyl chloride (7.90 mg, 0.0731 mmol) was added at 0°C. The mixture was stirred overnight at room temperature. 5 ml of water was added, and the mixture was extracted with DCM (5 mL x 3), washed with saturated brine (10 mL x 1), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by high pressure preparative liquid separation (chromatographic column model: Daisogei 30 mm*250 mm, C18, 10 um 100A, mobile phase: acetonitrile / water, gradient: 10%-30%, 30 min), and 8.00 mg of the title compound was obtained as a white solid, with a yield of 23.5%.
[0512] LC-MS: m / z 563.21 [M+H] + .
[0513] 1 H NMR (400MHz, DMSO-d6) δ7.39-7.28 (m, 3H), 7.24-7.16 (m, 3H), 7.14-7.10 (m, 1H), 5.54-5.47 (m, 1H), 5.43 (s, 2H), 4.79-4.68 (m, 1H), 4.5 4-4.30 (m, 2H), 4.25-4.05 (m, 2H), 3.84-3.73 (m, 1H), 3.68-3.56 (m, 1H), 3.13 (s, 3H), 3.07-2.92 (m, 2H), 2.1 (s, 3H), 2.72-2.62 (m, 1H).
[0514] Example 22: Preparation of (S)-3-(2-benzyl-3-chloro-7-oxo-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)-1-methyl-9-(morpholinosulfonyl)-3,4,8,9,10,11-hexahydro-[1,4]oxazepino[3,2-f]isoquinolin-2(1H)-one (22)
[0515]
[0516] Step 1: Preparation of (S)-3-(2-benzyl-3-chloro-7-oxo-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)-1-methyl-9-(morpholinosulfonyl)-3,4,8,9,10,11-hexahydro-[1,4]oxazepino[3,2-f]isoquinolin-2(1H)-one (22)
[0517] At room temperature, compound 18 (30.0 mg, 0.0610 mmol) was dissolved in DCM (2 ml), and DIEA (15.7 mg, 0.122 mmol) was added to the reaction solution. At 0°C, morpholine-4-sulfonyl chloride (13.6 mg, 0.0731 mmol) was added and stirred at room temperature overnight. 5 ml of water was added, DCM was extracted (5 mL x 3), washed with saturated brine (10 mL x 1), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by high pressure preparative liquid separation (chromatographic column model: Daisogei 30 mm × 250 mm, C18, 10 um 100A, mobile phase: acetonitrile / water, gradient: 10%-30%, 30 min) to obtain 6.00 mg of the title compound as a white solid, with a yield of 15.4%.
[0518] LC-MS: m / z 641.19 [M+H] + .
[0519] 1 H NMR (400MHz, DMSO-d6) δ7.38-7.29(m, 3H), 7.26-7.22(m, 1H), 7.20-7.14(m, 3H ), 5.53-5.47(m, 1H), 5.43(s, 2H), 4.77-4.70(m, 1H), 4.59-4.53(m, 1H), 4.47-4 .41(m,1H),4.26-4.16(m,2H),4.13-4.01(m,2H),3.88-3.81(m,1H),3.67-3.5 8(m, 5H), 3.20-3.15(m, 4H), 3.13(s, 3H), 3.19-2.91(m, 4H), 2.73-2.63(m, 3H).
[0520] Example 23: Preparation of (S)-3-(2-benzyl-3-chloro-7-oxo-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)-1-methyl-9-(methylsulfonyl)-3,4,8,9,10,11-hexahydro-[1,4]oxazepino[3,2-f]isoquinolin-2(1H)-one (23)
[0521]
[0522] The title compound 23 was prepared in the same manner as in Example 8, except that (S)-3-(2-benzyl-3-chloro-7-oxo-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)-1-methyl-3,4,8,9,10,11-hexahydro-[1,4]oxazepin[3,2-f]isoquinolin-2(1H)-one (18) was used instead of (S)-3-(2-benzyl-3-chloro-7-oxo-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)-5-methyl-2,3,7,8,9,10-hexahydro-[1,4]oxazepin[2,3-g]isoquinolin-4(5H)-one (6).
[0523] LC-MS: m / z 570.15 [M+H] + .
[0524] 1 H NMR (400MHz, CDCl3) δ7.33-7.31 (m, 3H), 7.30-7.27 (m, 2H), 7.11-7.06 (m, 2H), 5.88 (t, 1H), 5.43 (br, 2H), 5.41 (s, 2H), 4.78 (d, 1H), 4.56 (t, 1H) ), 4.24-4.31(m, 3H), 4.06-4.08(m, 1H), 3.58-3.54(m, 1H), 3.24(s, 3H) , 3.06-3.02(m, 3H), 2.84(s, 3H), 2.80-2.71(m, 1H), 2.69-2.67(m, 1H).
[0525] Example 24: Preparation of (S)-3-(2-benzyl-3-chloro-7-oxo-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)-9-(cyclopropanecarbonyl)-1-methyl-3,4,8,9,10,11-hexahydro-[1,4]oxazepino[3,2-f]isoquinolin-2(1H)-one (24)
[0526]
[0527] The title compound 24 was prepared in the same manner as in Example 11, except that (S)-3-(2-benzyl-3-chloro-7-oxo-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)-1-methyl-3,4,8,9,10,11-hexahydro-[1,4]oxazepin[3,2-f]isoquinolin-2(1H)-one (18) was used instead of (S)-3-(2-benzyl-3-chloro-7-oxo-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)-5-methyl-2,3,7,8,9,10-hexahydro-[1,4]oxazepin[2,3-g]isoquinolin-4(5H)-one (6).
[0528] LC-MS: m / z 570.20 [M+H] + .
[0529] 1 H NMR (400MHz, DMSO-d6) δ7.38-7.33(m, 3H), 7.32-7.30(m, 1H), 7.32-7.21(m, 3H), 5. 56-5.43(m, 1H), 5.43(br, 2H), 4.97-4.91(m, 1H), 4.78-4.71(m, 1H), 4.42-4.37(m, 1 H), 4.28-4.22(m, 1H), 4.24-4.18(m, 1H), 4, 11-4.07(m, 1H), 3.65-362(m, 1H), 3.12( br, 3H), 2.84-2.76 (m, 1H), 2.71-2.65 (m, 4H), 2.11-2.08 (m, 1H), 0.78-0.75 (m, 4H).
[0530] Example 25: Preparation of (S)-3-(2-benzyl-3-chloro-7-oxo-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)-1-methyl-2-oxo-1,2,3,4,10,11-hexahydro-[1,4]oxazepino[3,2-f]isoquinoline-9(8H)-carbonitrile (25)
[0531]
[0532] The title compound 25 was prepared in the same manner as in Example 10, except that (S)-3-(2-benzyl-3-chloro-7-oxo-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)-1-methyl-3,4,8,9,10,11-hexahydro-[1,4]oxazepin[3,2-f]isoquinolin-2(1H)-one (18) was used instead of (S)-3-(2-benzyl-3-chloro-7-oxo-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)-5-methyl-2,3,7,8,9,10-hexahydro-[1,4]oxazepin[2,3-g]isoquinolin-4(5H)-one (6).
[0533] LC-MS: m / z 517.17 [M+H] + .
[0534] 1HNMR (400MHz, CDCl3) δ7.32-7.23(m, 5H), 7.10-7.07(m, 1H), 7.02-6.99(m, 1H), 5.85(t, 1H), 5.39(s, 2H), 4.61-4.48(m , 3H), 4.34-4.25(m, 2H), 3.78-3.74(m, 1H), 3.58-3.55(m, 1H), 3.34-3.27(m, 1H), 3.03-2.99(m, 3H), 2.77-2.70(m, 2H).
[0535] Example 26: Preparation of (S)-3-(2-benzyl-3-chloro-7-oxo-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)-1,9-dimethyl-3,4,8,9,10,11-hexahydro-[1,4]oxazepino[3,2-f]isoquinolin-2(1H)-one (26)
[0536]
[0537] The title compound 26 was prepared in the same manner as in Example 7, except that (S)-3-(2-benzyl-3-chloro-7-oxo-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)-1-methyl-3,4,8,9,10,11-hexahydro-[1,4]oxazepin[3,2-f]isoquinolin-2(1H)-one (18) was used instead of (S)-3-(2-benzyl-3-chloro-7-oxo-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)-5-methyl-2,3,7,8,9,10-hexahydro-[1,4]oxazepin[2,3-g]isoquinolin-4(5H)-one (6).
[0538] LC-MS: m / z 506.17 [M+H] + .
[0539] 1H NMR (400MHz, CDCl3) δ7.29-7.26 (m, 3H), 7.23 (s, 2H), 5.88-5.83 (m, 1H), 5.39 (s, 2H), 4.57-4.51 (s, 1H), 4.30-4. 25 (m, 1H), 4.02 (s, 2H), 3.56-3.51 (m, 3H), 3.21 (s, 3H), 3.10-3.00 (m, 2H), 2.69-2.64 (m, 3H), 2.64-2.58 (m, 3H).
[0540] Example 27: Preparation of (S)-3-(2-benzyl-3-chloro-7-oxo-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)-N,N,1-trimethyl-2-oxo-1,2,3,4,10,11-hexahydro-[1,4]oxazepino[3,2-f]isoquinoline-9(8H)-sulfonamide (27)
[0541]
[0542] The title compound 27 was prepared in the same manner as in Example 9, except that (S)-3-(2-benzyl-3-chloro-7-oxo-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)-1-methyl-3,4,8,9,10,11-hexahydro-[1,4]oxazepin[3,2-f]isoquinolin-2(1H)-one (18) was used instead of (S)-3-(2-benzyl-3-chloro-7-oxo-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)-5-methyl-2,3,7,8,9,10-hexahydro-[1,4]oxazepin[2,3-g]isoquinolin-4(5H)-one (6).
[0543] LC-MS: m / z 598.12 [M+H] + .
[0544] 1H NMR (300MHz, DMSO-d6) δ7.40-7.27 (m, 3H), 7.26-7.08 (m, 4H), 5.55-5.34 (m, 3H), 4.72 (t, J=10.9Hz, 1H), 4.60-4.32 (m, 2H), 4.18 (t, J=9. 2Hz, 1H), 4.13-4.00(m, 1H), 3.89-3.73(m, 1H), 3.68-3.50(m, 1H), 3.24-3.05(m, 5H), 3.04-2.85(m, 1H), 2.78(s, 7H), 2.73-2.57(m, 2H).
[0545] Example 28: Preparation of (S)-3-(2-benzyl-3-chloro-7-oxo-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)-1-methyl-9-(tetrahydro-2H-pyran-4-carboxylate)-3,4,8,9,10,11-hexahydro-[1,4]oxazepino[3,2-f]isoquinolin-2(1H)-one (28)
[0546]
[0547] The title compound 28 was prepared in the same manner as in Example 23, except that tetrahydro-2H-pyran-4-carbonyl chloride was used instead of methanesulfonyl chloride.
[0548] LC-MS: m / z 604.22 [M+H] + .
[0549] 1 H NMR (400MHz, CDCl3) δ7.35-7.28(m, 3H), 7.25-7.19(m, 2H), 7.16-7.01(m, 2H), 5.91-5.85(m, 1H), 5.39(br, 2H), 5.12-5.07(m, 1H), 4.75-4.51(m, 2H), 4.46-4. 41(m, 1H), 4.38-4.24(m, 2H), 4.13-4.00(m, 2H), 3.62-3.42(m, 3H), 3.21(br, 3 H), 3.13-2.97(m, 1H), 2.92-2.59(m, 4H), 2.11-1.84(m, 2H), 1.80-1.68(m, 2H).
[0550] Example 29: Preparation of (S)-3-(2-benzyl-3-chloro-7-oxo-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)-1-methyl-9-(4-methylpiperazine-1-carboxylate)-3,4,8,9,10,11-hexahydro-[1,4]oxazepino[3,2-f]isoquinolin-2(1H)-one (29)
[0551]
[0552] The title compound 29 was prepared in the same manner as Example 23, except that 4-methylpiperazine-1-carbonyl chloride was used instead of methanesulfonyl chloride.
[0553] LC-MS: m / z 517.17 [M+H] + .
[0554] 1 H NMR (400MHz, CDCl3) δ8.31 (br, 1H), 7.32-7.29 (m, 3H), 7.25-7.21 (m, 2H), 7.04 (s, 2H), 5.90-5.83 (m, 1H), 5.41 (br, 2H), 4.56-4.4 1(m, 2H), 4.31-4.25(m, 2H), 3.94-3.91(m, 1H), 3.62-3.34(m, 7H), 3.21(s, 3H), 3.15-2.84(m, 3H), 2.75-2.62(m, 5H), 2.47(s, 3H).
[0555] Biological experiments
[0556] Test Example 1: Analysis of the Inhibitory Activity of the Compounds of the Present Invention on U937 Cell Necrosis in Vitro
[0557] Receptor interacting protein kinase 1 (RIP1) activation can induce necrosis of human monocytic leukemia U937 cells. Therefore, the activity of the compounds of the present invention was tested by an in vitro cell necrosis assay using human monocytic leukemia U937 cells (CBP60277, CoBioer).
[0558] ATP adenosine triphosphate participates in a variety of enzymatic reactions in the body and is an indicator of living cell metabolism. Its content directly reflects the number and state of cells. Add the corresponding volume of CellTiter-GloTM reagent (Promega) to the cell culture medium and measure the luminescence value. The luminescence value is proportional to the amount of ATP, and ATP is positively correlated with the number of living cells. Cell viability can be determined by detecting the ATP content.
[0559] Test method:
[0560] a. Cells were cultured in RPMI 1640 medium (31800-500, Solarbio) supplemented with 10% fetal bovine serum (10099141, Gibco), 100 U / mL penicillin and 100 μg / mL streptomycin (15140122, Invitrogen). 5 The cells / mL were suspended in RPMI 1640 medium supplemented with 1% fetal bovine serum, 100 U / mL penicillin, and 100 μg / mL streptomycin. The cell suspension was added to a 384-well plate (3570, Corning), 35 μL per well, i.e., 17,500 U937 cells / well.
[0561] b. Dilute 10mM QVD (Q-VD-OPh) (Cat. No.: 551476, EMD Millipore Corp) stock solution (QVD is dissolved in 100% DMSO to prepare a 10mM stock solution) 40 times to 250μM with RPMI1640 culture medium containing 1% fetal bovine serum, 100U / mL penicillin, and 100μg / mL streptomycin. Take 5μL of QVD and add it to the corresponding cell wells. The final reaction system is 50μL, and the final concentration of QVD is 25μM.
[0562] c. A 10 mM stock solution of the compound of the present invention was used as the starting concentration (the compound of the present invention was dissolved in 100% DMSO to prepare a 10 mM stock solution), and dilution was performed in a 96-well dilution plate (249944, Nunc) at a ratio of 1:3. The gradient concentration of the compound was 10000 μM, 3333.33 μM, 1111.11 μM, 370.37 μM, 123.46 μM, 41.15 μM, 13.72 μM, 4.57 μM, and 0 μM.
[0563] d. The above compounds diluted in 100% DMSO were diluted 100 times with RPMI 1640 medium containing 1% fetal bovine serum, 100 U / mL penicillin, and 100 μg / mL streptomycin.
[0564] e. Take 5 μL of the diluted compound in step d and add it to the cells in a 384-well plate. The final concentrations of the compound are 10000 nM, 3333.33 nM, 1111.11 nM, 370.37 nM, 123.46 nM, 41.15 nM, 13.72 nM, 4.57 nM, and 0 nM.
[0565] f. Incubate in a 37°C, 5% CO2 incubator for 30 minutes.
[0566] g. After culture, dilute the TNFα (PHC3016, Gibco) stock solution (TNFα is dissolved in sterile water to prepare a 100 μg / mL stock solution) 100 times to 1 μg / mL with RPMI 1640 medium containing 1% fetal bovine serum, 100 U / mL penicillin, and 100 μg / mL streptomycin. Take 5 μL of TNFα and add it to the corresponding cell wells. The final reaction system is 50 μL, and the final concentration of TNFα is 100 ng / mL.
[0567] h. Place the cell culture plate in an incubator at 37°C, 5% CO2 and culture overnight.
[0568] i. Take out the cells from the 384-well plate and equilibrate at room temperature for 30 minutes.
[0569] j. Add 30 μL CellTiter-Glo to each test well. TM Reagents, vortex to mix, and incubate at room temperature for 10 minutes.
[0570] k. Detect chemiluminescent signal using Cytation 3.
[0571] Using GraphPad Prism 5 software, the IC of the compound was obtained using the following nonlinear fitting formula: 50 :
[0572] Y=Bottom+(Top-Bottom) / (1+10^((Log EC 50 -X)×Hillslope)),
[0573] Among them, X is the logarithmic value of the compound concentration, Y is the efficacy of the compound in inhibiting cell necrosis; Top and Bottom are the Y values of the highest and lowest plateaus of the curve; Hillslope is the Hill constant.
[0574] The activity of the compounds of the present invention in inhibiting U937 cell necrosis is shown in Table 1 below.
[0575] In Table 1, A refers to the IC of the compound for inhibiting cell necrosis. 50 <10nM; B means 10nM<IC 50 <100nM; C means 100nM<IC 50 <500nM; D refers to IC 50 >500nM.
[0576] Table 1 IC of the compounds of the present invention for inhibiting U937 cell necrosis 50 value
[0577]
[0578]
[0579] Conclusion: The compounds of the present invention can effectively inhibit U937 cell necrosis.
[0580] Experimental Example 2: Inhibitory analysis of the activity of the compounds of the present invention on receptor interacting protein kinase 1 (RIP1)
[0581] The inhibitory effect of the compounds of the present invention on the activity of receptor interacting protein kinase 1 (RIP1) can be detected by ADP-Glo TM Kinase assay to detect. ADP-Glo TM The kinase assay is a luminescent kinase detection assay. ADP is generated during the autophosphorylation of RIP1, and ADP is converted into ATP, which is then converted into light by Ultra-Glo luciferase. ADP is quantified by detecting the light signal, thereby measuring the enzyme activity by quantifying the amount of ADP generated during the enzyme reaction. The analysis is performed in two steps: first, after the kinase reaction, an equal volume of ADP-Glo reagent is added to the kinase reaction system to terminate the reaction and consume the remaining ATP; second, a kinase detection reagent is added, which converts ADP into ATP while also using a coupled luciferase / luciferin reaction to detect newly synthesized ATP.
[0582] Test method:
[0583] a. Take 10 mM stock solution of the compound of the present invention as the starting concentration (the compound of the present invention is dissolved in 100% DMSO to prepare a 10 mM stock solution), and dilute it in an equal ratio of 1:3 in a compound dilution plate (781201-906, Greiner). The gradient concentration of the compound is 10000 μM, 3333.33 μM, 1111.11 μM, 370.37 μM, 123.46 μM, 41.15 μM, 13.72 μM, 4.57 μM, 1.52 μM, 0.51 μM, and 0 μM.
[0584] b. The compounds diluted with 100% DMSO were transferred from the compound dilution plate to the white OptiPlate-384F plate (6007290, PE) using Echo550 (LABCYTE), 10 nL per well, and then 90 nL DMSO was added to dilute 10 times, and 100 nL DMSO was transferred to each positive control well and negative control well. The final reaction system was 10 μL, and the final concentrations of the compounds were 10000 nM, 3333.33 nM, 1111.11 nM, 370.37 nM, 123.46 nM, 41.15 nM, 13.72 nM, 4.57 nM, 1.52 nM, 0.51 nM, and 0 nM.
[0585] c. Prepare reaction buffer: Prepare a buffer with a final concentration of 50 mM HEPES (PH7.5) (H3375, Sigma), 0.02% CHAPS (C3023, Sigma), 50 mM sodium chloride (7647-14-5, Sigma), 30 mM magnesium chloride (M1028-100 mL, Sigma), 1 mM dithiothreitol (43816-50 mL, Sigma), and 0.05% BSA (CR84-100, Sigma) using deionized water.
[0586] d. Dilute 0.794 μM GST-RIPK1 stock solution (R07-11G, SignalChem) to 40 nM with the above reaction buffer. Add 5 μL RIP1 enzyme solution to each well, the final reaction system is 10 μL, and the final concentration of RIP1 enzyme is 20 nM. Pre-incubate in a 25°C incubator for 30 minutes.
[0587] e. Dilute the ATP stock solution (V915B, Promega) in the 10mM ADP-Glo kit to 100μM with the above reaction buffer. Add 5μL of ATP solution to each well except the negative control well, and add 5μL of reaction buffer to each well of the negative control well. The final reaction system is 10μL, and the final ATP concentration is 50μM. Incubate in a 25℃ incubator for 4 hours.
[0588] f. Add 10 μL of ADP-Glo Reagent in the ADP-Glo Kit (V9102, Promega) to each well and incubate at 25°C for 40 minutes.
[0589] g. Add 20 μL of the detection reagent of the ADP-Glo kit to each well and incubate at 25°C for 30 minutes.
[0590] h. Chemiluminescence values were read using Envision (2014, PE).
[0591] The compound inhibition rate (inhibition %) was calculated using the following formula:
[0592]
[0593] S Test compound: Reading value of the well with compound sample added
[0594] S positive control: Reading value of wells with GST-RIPK1 enzyme and substrate added
[0595] S Negative control: Add reaction buffer without GST-RIP1 enzyme and read the value of the substrate well
[0596] The IC value of the compound was obtained by fitting the dose-effect curve using XLfit with inhibition percentage as the ordinate and compound concentration as the abscissa. 50 , the formula is as follows:
[0597] Y=Bottom+(Top-Bottom) / (1+10^((LogIC 50 -X)*HillSlope))
[0598] Wherein, X is the logarithmic value of the compound concentration, Y is the potency of the compound in inhibiting kinase; Top and Bottom are the Y values of the highest and lowest plateaus of the curve; Hillslope is the Hill constant.
[0599] The inhibitory effects of the compounds of the present invention on RIP1 activity are shown in Table 2 below.
[0600] In Table 2, A refers to the IC of the compound for inhibiting RIP1. 50 <10nM; B means 10nM<IC 50 <100nM; C means 100nM<IC 50 <500nM; D refers to IC 50 >500nM.
[0601] Table 2 IC of the compounds of the present invention for inhibiting RIP1 50 value
[0602]
[0603] Conclusion: The compounds of the present invention can effectively inhibit the activity of RIP1.
[0604] Test Example 3: Analysis of the in vitro inhibitory activity of the compounds of the present invention on L929 cell necrosis
[0605] The effects of the compounds of the present invention can be tested by in vitro cell necrosis assay using L929 cells (Nanjing Kebai). ATP adenosine triphosphate participates in a variety of enzymatic reactions in vivo and is an indicator of living cell metabolism. Its content directly reflects the number and state of cells. Add a corresponding volume of Promega's CellTiter-Glo to the cell culture medium. TM Reagent, measure the luminescence value, the luminescence value is proportional to the amount of ATP, and ATP is positively correlated with the number of living cells. Cell viability is determined by detecting the ATP content.
[0606] Test method:
[0607] a. Cells were cultured in MEM medium (11095-080, Invitrogen) supplemented with 10% fetal bovine serum (10099141, Gibco), 100 U / mL penicillin and 100 μg / mL streptomycin (15140122, Invitrogen). 4 The cells / mL were suspended in MEM medium supplemented with 1% fetal bovine serum, 100 U / mL penicillin, and 100 μg / mL streptomycin. The cell suspension was added to a 384-well plate (3570, Corning), 35 μL per well, i.e., 1750 L929 cells / well.
[0608] b. A 30 mM stock solution of the compound of the present invention was used as the starting concentration (the compound of the present invention was dissolved in 100% DMSO to prepare a 30 mM stock solution) and diluted in a 96-well dilution plate (249944, Nunc) at a ratio of 1:3. The gradient concentration of the compound was 30000 μM, 10000 μM, 3333.33 μM, 1111.11 μM, 370.37 μM, 123.46 μM, 41.15 μM, 13.72 μM, 4.57 μM, and 0 μM.
[0609] c. The above compounds diluted in 100% DMSO were diluted 100 times with MEM medium containing 1% fetal bovine serum, 100 U / mL penicillin, and 100 μg / mL streptomycin.
[0610] d. Take 5 μL of the diluted compound in step c and add it to the cells in a 384-well plate. The total reaction system is 50 μL. The final concentrations of the compounds are 30000 nM, 10000 nM, 3333.33 nM, 1111.11 nM, 370.37 nM, 123.46 nM, 41.15 nM, 13.72 nM, 4.57 nM, and 0 nM.
[0611] e. Incubate in a 37°C, 5% CO2 incubator for 30 minutes.
[0612] f. Dilute 10 mM QVD (551476, EMD) stock solution (QVD is dissolved in 100% DMSO to prepare a 10 mM stock solution) 40 times to 250 μM with MEM medium containing 1% fetal bovine serum, 100 U / mL penicillin, and 100 μg / mL streptomycin.
[0613] g. Dilute the mTNFα (50349-MNAE, Sino Biological) stock solution (TNFα was dissolved in sterile water to prepare a 590 μg / mL stock solution) 590 times to 1 μg / mL with MEM medium containing 1% fetal bovine serum, 100 U / mL penicillin, and 100 μg / mL streptomycin.
[0614] h. Mix the intermediate diluted QVD and mTNFα at a ratio of 1:1.
[0615] i. Take 10 μl of the mixture of QVD and mTNFα and add it to the corresponding cell wells. The final reaction system is 50 μl, the final concentration of QVD is 25 μM, and the final concentration of mTNFα is 100 ng / mL.
[0616] j. Place the cell culture plate in an incubator at 37°C, 5% CO2 for 48 hours.
[0617] k. Take out the cells from the 384-well plate and equilibrate at room temperature for 30 minutes.
[0618] l. Add 30 μL of CellTiter-Glo™ reagent to each test well, shake to mix, and incubate at room temperature for 10 minutes.
[0619] m. Detect chemiluminescent signal using Cytation 3.
[0620] n. Using GraphPad Prism 5 software, the EC50 of the compound was obtained using the following nonlinear fitting formula:
[0621] Y=Bottom+(Top-Bottom) / (1+10^((Log EC 50 -X)×Hillslope)),
[0622] Among them, X is the logarithmic value of the compound concentration, Y is the efficacy of the compound in inhibiting cell necrosis; Top and Bottom are the Y values of the highest and lowest plateaus of the curve; Hillslope is the Hill constant.
[0623] The activity of the compounds of the present invention in inhibiting L929 cell necrosis is shown in Table 3 below.
[0624] In Table 3, A refers to the IC of the compound for inhibiting cell necrosis. 50 <50nM; B means 50nM<IC 50 <100nM; C means 100nM<IC 50 <500nM; D refers to IC 50 >500nM.
[0625] Table 3 IC of the compounds of the present invention for inhibiting L929 cell necrosis 50 value
[0626]
[0627] Conclusion: The compounds of the present invention can inhibit L929 cell necrosis.
[0628] Test Example 4: Pharmacokinetic evaluation of the compounds of the present invention in Wistar rats and ICR mice
[0629] The compounds of the present invention were orally administered to male 6-week-old Wistar rats and male 7-week-old ICR mice (Beijing Weitong Lihua Experimental Animal Technology Co., Ltd.). Orbital blood was collected at 0, 0.167, 0.25, 0.50, 1.00, 2.00, 4.00, 6.00, 8.00 and 24.00 h before and after administration. The blood was anticoagulated with dipotassium ethylenediaminetetraacetic acid, centrifuged at 4 ° C, 3500 rpm for 10 minutes, and plasma was obtained and stored at -20 ° C until testing. Take 50 μL of plasma sample in a 1.5 mL EP tube, add 400 μL of acetonitrile working solution containing 5 ng / mL verapamil hydrochloride (internal standard), vortex for 1 minute to mix thoroughly, and centrifuge at 10000 rpm for 10 minutes. 0.2 mL of the supernatant was removed, filtered through a 0.22 μM organic membrane (AS081320-T, Agela Technologies), added to an injection vial, and analyzed by LC / MS (Waters, Waters UPLC I Class, TQ-S micro) to obtain the blood drug concentration, and the pharmacokinetic parameters were analyzed by DAS software 3.3.0.
[0630] The pharmacokinetic experimental data of the compound of the present invention after oral administration are shown in Table 4.
[0631] In Table 4, A refers to the AUC of the compound. 0-t (μg / L*h)<500; B means 500<AUC 0-t (μg / L*h)<1000; C means 1000<AUC 0-t (μg / L*h)<5000; D means 5000<AUC 0-t (μg / L*h)<10000.
[0632] Table 4 Pharmacokinetic parameters of the compounds of the present invention after single oral administration to male Wistar rats and male ICR mice
[0633]
[0634] Conclusion: The compounds of the present invention have good in vivo pharmacokinetic properties after oral administration to rats and mice.
[0635] Test Example 5: Blood-brain barrier permeability test of the compound of the present invention in C57BL / 6J mice
[0636] The compound of the present invention was orally administered to male 6-week-old C57BL / 6 mice (Beijing Weitong Lihua Experimental Animal Technology Co., Ltd.). Blood and brain tissue of mice were collected at 0, 0.25, 1.00 and 4.00 h before and after administration. Before taking brain tissue, 10 mL of normal saline was perfused from the left ventricle of the mouse. The blood sample was anticoagulated with dipotassium ethylenediaminetetraacetic acid, centrifuged at 4°C, 3500 rpm for 10 minutes, and plasma was obtained and stored at -20°C until testing. After the brain tissue was rinsed with normal saline, the dry weight was weighed and transferred to a 10 mL EP tube. Normal saline was added according to body weight for homogenization (brain weight: normal saline volume = 1:2), and the volume was uniformly fixed to 2 mL after homogenization to ensure that the whole process was carried out at low temperature. Accurately measure 50 μL of brain tissue homogenate sample, transfer to a 1.5 mL EP tube, add 400 μL of acetonitrile working solution containing 5 ng / mL verapamil hydrochloride (internal standard), vortex vigorously shake for 1 min, and centrifuge at 16000 rpm for 10 min. Take the supernatant, filter it with a 0.22 μtm organic membrane (AS081320-T, Agela Technologies), and add it to the injection vial for testing. The blood drug concentration and brain tissue drug concentration were analyzed by LC / MS (Waters, Waters UPLC I Class, TQ-Smicro).
[0637] The blood-brain barrier permeability of the compounds of the present invention after oral administration is shown in Table 5.
[0638] Compound <![CDATA[C b / C p @1h]]> Example 2 >1 Embodiment 14 <1
[0639] Note: C b (ng / g): drug concentration in brain tissue, C p (ng / mL): drug concentration in plasma.
[0640] It can be seen from the above experimental results that the drug concentration in brain tissue of Example 2 of the present invention is greater than that in plasma, while the drug concentration in plasma of Example 14 is greater than that in brain tissue.
Claims
1. A compound represented by general formula (III) or a pharmaceutically acceptable salt thereof, in, X is selected from -O-; Y 1 and Y 2 Each is independently selected from O; L is selected from -CH2-; Ring A is selected from phenyl, wherein the phenyl is optionally further substituted with one or more R 9 replace; Selected from Ring E is selected from R 1 and R 4 is hydrogen; R 5 Selected from C 1-6 alkyl; Each R 8 are each independently selected from hydrogen and halogen; Each R 9 are each independently selected from hydrogen and halogen; q is 0 or 1.
2. A compound or a pharmaceutically acceptable salt thereof, wherein the compound is selected from:
3. A method for preparing a compound represented by general formula (III) or a pharmaceutically acceptable salt thereof according to claim 1, comprising the following steps: In the presence of a catalyst, compound III1 undergoes an intramolecular ring-closing reaction to obtain a compound of formula (III); Among them, X, L, ring A, ring E, R 1 , R 4 , R 5 As defined in claim 1. The preparation method according to claim 3 , wherein the catalyst is trimethylaluminum.
5. A pharmaceutical composition comprising the compound according to claim 1 or 2 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.
6. Use of the compound according to claim 1 or 2 or a pharmaceutically acceptable salt thereof or the pharmaceutical composition according to claim 5 in the preparation of a receptor interacting protein kinase 1 (RIP1) inhibitor.
7. Use of the compound according to claim 1 or 2 or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition according to claim 5, in the preparation of a medicament for preventing or treating a disease associated with receptor interacting protein kinase 1 activity.
8. The use according to claim 7, wherein the disease is selected from inflammatory diseases, autoimmune diseases or nervous system diseases.
9. The use according to claim 8, wherein the inflammatory disease and autoimmune disease are rheumatoid arthritis, ulcerative colitis, Crohn's disease, psoriasis, retinal detachment, retinitis pigmentosa, macular degeneration, pancreatitis, spondyloarthritis, gout, juvenile idiopathic arthritis, systemic lupus erythematosus, Sjögren's syndrome, systemic sclerosis, antiphospholipid syndrome, vasculitis, osteoarthritis, nonalcoholic fatty liver disease, autoimmune hepatobiliary disease, primary sclerosing cholangitis, nephritis, celiac disease, autoimmune Immune thrombocytopenic purpura, transplant rejection, solid organ ischemia-reperfusion injury, sepsis, systemic inflammatory response syndrome, allergic diseases, asthma, atopic skin diseases, multiple sclerosis, type I diabetes, orbital necrotizing granulomatosis, pulmonary sarcoidosis, Behcet's disease, interleukin-1 converting enzyme associated febrile syndrome, chronic obstructive pulmonary disease, tumor necrosis factor receptor-associated syndrome or periodontitis; the nervous system disease is Huntington's disease, Alzheimer's disease, Parkinson's disease or amyotrophic lateral sclerosis.
Citation Information
Patent Citations
Heterocyclic compound
CN108431004A
Heterocyclic compound and salt thereof, preparation method, application and medicine
CN109134448A
Azeepine fused ring compound and medical application thereof
CN115867557A
N-[4-oxo-2,3-dihydro-1,5-benzoxazepin-3-yl]-5,6-dihydro-4h-pyrrolo[1,2-b]pyrazol e-2-carboxamide derivatives and related compounds as rip1 kinase inhibitors for treating e.g. irritable bowel syndrome (IBS)
WO2019204537A1
Cell necrosis inhibitor, preparation method therefor and use thereof
WO2020001420A1
